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Ovarian cancer comprises a diverse set of diseases that are difficult to detect and treat 
successfully.  Improving outcomes for ovarian cancer patients is contingent upon identifying 
targeted, individualized therapeutic strategies.  One promising but under-utilized target is 
estrogen receptor-alpha (ER).  ER is expressed in ~70% of epithelial ovarian cancers and 
epidemiologic studies implicate a role for estrogen in ovarian tumorigenesis.  Further, clinical 
data suggest that a subset of ovarian cancer patients benefit from endocrine therapy.  We 
hypothesized that ER drives development and progression of a subset of ovarian tumors and that 
outputs of ER function would identify patients who respond to endocrine therapy.  We assessed 
endocrine response and mechanisms of ER signaling in models and clinical samples of high-
grade serous ovarian cancer (HGSOC).  These studies suggested that expression of ER target 
genes (ERTGs) reflect active ER in HGSOC and correspond with endocrine responsiveness.  In 
light of this, we profiled ERTG expression to evaluate changes in ER signaling during the 
progression from benign endometriosis to endometriosis-associated cancer (EAOC).  This 
analysis suggested that canonical ER signaling becomes largely inactivated during this 
transformation and that de-repressed genes (e.g. FGF18, ESR2) may contribute to the evolution 
of EAOC.  Finally, we compared ER and ERTG expression between serous and mucinous low 
malignant potential (LMP) tumors. Serous LMP tumors have high expression of ER and several 
ERTGs (e.g. GREB1).  Taken together, our findings describe biomarkers that could identify 
TARGETING ESTROGEN RECEPTOR AS A STRATEGY FOR 
PERSONALIZED MEDICINE IN OVARIAN CANCER 
Courtney L. Andersen, PhD 
University of Pittsburgh, 2016
 
 v 
ovarian cancer patients across multiple disease subtypes who would benefit clinically from 
endocrine therapy. 
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1.0  INTRODUCTION 
1.1 OVARIAN CANCER 
Ovarian cancer is the most common gynecologic malignancy and the fifth leading cause of 
cancer death in women1.  An estimated 22,300 women in the United States will be diagnosed 
with ovarian cancer in 2016 and an estimated 14,300 (~40%) will succumb to the disease1.  The 
poor survival rate is attributable to two main factors.  Firstly, ovarian cancer lacks effective 
detection/screening methods and patients present with vague symptoms (e.g. gastrointestinal 
discomfort, appetite loss, weight gain, dull pelvic pain)2,3.  As such, the disease is often 
diagnosed at an advanced, metastatic stage.  The second factor is a paucity of effective treatment 
options.  Development of successful treatment strategies for ovarian cancer has been impeded by 
the complex and heterogeneous biology of the disease: despite the uniform classification as 
“ovarian” cancer, the moniker represents a broad range of malignancies including epithelial 
ovarian cancer, germ cell stromal tumors (e.g. granulosa cell tumors and Sertoli-Leydig tumors), 
sex chord stromal tumors (e.g. yolk sac and choriocarcinomas), and small cell carcinomas4.  Of 
these, epithelial ovarian cancers account for 95% of all cases and were the focus of this work.  
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1.1.1 Heterogeneity of epithelial ovarian cancer 
Epithelial ovarian cancer is a diverse class of diseases in and of itself.  It can be further divided 
into borderline tumors (also referred to as tumors of low malignant potential or LMPs) and 
invasive cancers.  Invasive cancers are then further sub-classified into histologic subtypes 
including high-grade serous, which accounts for ~70% of cases; endometrioid (~10-15% of 
cases); clear cell (~10%); and mucinous (1.5%)5,6.  Subtype is determined by pathologic review 
of a specimen collected at primary surgery.  However, the subtypes are as distinct molecularly as 
they are histologically. While endometrioid and clear cell tumors share a propensity for 
ARID1A, CTNNB1, PIK3CA, and PTEN mutations7, mucinous tumors most frequently harbor 
KRAS alterations8.  Conversely, high-grade serous ovarian cancer (HGSOC) is characterized by 
ubiquitous p53 mutations, a propensity for DNA repair deficiencies, and rampant copy number 
aberrations but few recurrent somatic mutations9,10.  Further, HGSOC contains multiple 
molecular subgroups, differentiated by gene expression profiles and patient outcomes9,11, 
These type-specific molecular alterations suggest ovarian cancer subtypes arise through 
unique mechanisms of transformation.  Supporting this notion, the different subtypes are 
postulated to originate from different organs.  Preclinical and clinical evidence suggests HGSOC 
primarily originates from intraepithelial lesions of the distal fallopian tube12,13 whereas 
endometrioid and clear cell tumors are thought to arise from endometriosis lesions14–18.  
Mucinous tumors are believed to either be metastases to the ovary from primary gastrointestinal 
malignancies or arise from associated low malignant potential tumors5.  Taken together, the 
varying tissues of origin and stark differences at the histologic and molecular level suggest that 
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“ovarian” cancer is not one disease but many; these distinct subgroups will likely require unique 
therapies to effectively treat patients. 
1.1.2 Ovarian cancer treatment paradigms 
All epithelial ovarian cancers, regardless of subtype, are currently given the same first-line 
treatment: aggressive cytoreductive (“debulking”) surgery and platinum/taxane-based 
chemotherapy19.  This treatment paradigm dates back to 1976 and the advent of cisplatin.  Prior 
treatment for ovarian cancer relied on alkylating agents such as cyclophosphamide and 
melphalan20.  However, a series of trials in the 70s and 80s demonstrated that most ovarian 
tumors had a remarkable sensitivity to platinum, even in the setting of resistance to alkylating 
agents21–23.  The replacement of alkylating agents with taxanes as a partner for platinum further 
increased therapeutic response24.  The current modality of carboplatin and paclitaxel co-
treatment leads to ~80% patients achieving remission. 
Based on the length of their initial remission, patients are classified into one of three 
groups: platinum sensitive (recurrence >6 months after therapy), platinum resistance (recurrence 
within 6 months of therapy), or platinum refractory (progression while on therapy)25,26.  The 
favorable response to initial platinum prompts physicians to re-challenge tumors with platinum 
as second- and sometimes third-line therapy25.  If tumors become platinum resistant, other 
cytotoxic regimens (e.g. doxorubicin, topotecan, gemcitabine) are given at the discretion of the 
oncologist.  Despite the high platinum sensitivity in primary ovarian cancer, however, the 
majority of patients will develop chemotherapy resistance, relapse, and ultimately succumb to 
the disease19.  Identifying targeted, personalized treatment strategies for ovarian cancer will be 
paramount for improving patient survival. 
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1.1.3 Targeted therapeutics in ovarian cancer 
Numerous strategies for targeted therapy in ovarian cancer have been explored, in each case 
reporting only small response rates.  A phase II trial of trastuzumab, a monoclonal antibody 
against Her2, reported partial or complete responses in 7.3% of patients and disease stabilization 
in 39%27.  Similarly, a phase II study of gemcitabine plus pertuzumab, another Her2-targeted 
antibody, reported an overall response rate of 13.8% (compared to 4.6% for gemcitabine 
alone)28.  Conversely, a trial evaluating lapatinib, a combined Her2/EGFR inhibitor, reported no 
objective responses but did observe disease stabilization in 8% of patients29.  Other small 
molecule inhibitors including imatinib, and temsirolimus (mTOR) had similar results 
(summarized in Table 1).  Hormonal agents such as mifepristone, a progesterone receptor (PR) 
and glucocorticoid receptor (GR) antagonist, have also been evaluated (discussed further in 
section 1.2).  As a result of these low objective response rates, very few targeted agents have 
been evaluated in ovarian cancer in a phase III setting and only two targeted have been approved 
to date.  
Table 1: Selected trials of targeted therapy in epithelial ovarian cancer 
Drugs Target(s) Trials Response (complete or partial) 
Disease 
stabilization 
Trastuzumab Her2 Bookman et al. 200327 7% 39% 
Pertuzumab Her2 Makhija et al. 2010, Gordon et al. 200628,30 4.3 and 13.8% NA or 6.8% 
Lapatinib Her2, EGFR Garcia et al. 2012, Weroha et al. 2011 0 and 5% 8 and 16.6% 
Erlotinib EGFR, Her2 Vergote et al. 2014 0 0 
Imatinib Abl, PDGFR, c-kit 
Coleman et al., 2006, 
Matei et al. 2008, 
Schilder et al., 200831–33 
0-21.7% 12.5-33% 
Dasatinib Src  Schilder et al. 201234 0 20% 
Temsirolimus mTOR Behbakht et al. 201135 19% 24.1% 
Sunitinib  PDGF Campos et al. 201336 8.3% 36% 
Mifepristone PR, GR Rocereto et al. 2000, Rocerteo et al. 201037,38 4.5 and 26% NA or 12.5% 
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The first approved targeted agent for ovarian cancer was bevacizumab, an anti-VEGF 
antibody that inhibits angiogenesis39. Bevacizumab approval was based on several phase II and 
III trials that reported a significant improvement in progression-free survival (PFS) compared to 
controls39.  However, this improvement amounted empirically to only an additional three months 
of PFS and in most trials involved combining Bevacizumab with conventional chemotherapy39.  
As such, Bevacizumab was approved for use in combination with a topoisomerase inhibitor.  
Bevacizumab in combination with chemotherapy comes with myriad side effects including 
hemorrhage, blurred vision, fatigue, and potentially fatal gastrointestinal perforations and at a 
hefty price: the drug costs $3,000-5000 / cycle40,41. 
The other approved targeted agent for ovarian cancer is olaparib, a poly-ADP ribose 
polymerase (PARP) inhibitor.  Olaparib was approved for BRCA1/2 mutation carriers whose 
tumors have failed three previous rounds of chemotherapy42.  Despite 3% of HGSOC tumors 
harboring somatic alterations in BRCA1 or BRCA2 and 18% harboring another form of 
homologous repair (HR) defect (e.g. RAD51 inactivation)9, olaparib approval from the FDA 
only covers patients with germline BRCA1/2 mutations.  However, a trial of olaparib in patients 
with any HR defect is now ongoing (NCT02392676). 
The by and large failure of targeted agents in the ovarian cancer arena perhaps reflects 
poor patient rather than poor therapeutic selection.  While several trials did select patients based 
on biomarker expression (e.g. imatinib trials31,32, trastuzumab trial27), many of the clinical trials 
recruited patients regardless of target status (e.g. the lapatinib trials29,43).  This “all-comers” 
approach could mute any subgroup-specific responses.  While biomarker-based trials to date 
have still only reported low response rates, this should prompt further molecular and preclinical 
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studies to understand the biology of responsive tumors rather than abandonment of an entire 
therapeutic strategy. 
1.1.4 Opportunities for personalized medicine in ovarian cancer 
The unique genomic alterations in distinct histologic subtypes of ovarian cancer comprise many 
potential avenues for personalized therapy in ovarian cancer.  Targeting BRCA1/2-deficient 
tumors with olaparib is one such strategy.  Another example is MYC; MYC is amplified in 
>20% of HGSOC9 and preclinical data suggests inhibiting bromodomain proteins (e.g. BRD4) is 
effective against MYC-driven cancers44.  Further, preclinical studies have indicated ARID1A-
deficient cancers can be successfully treated by targeting ARID1B45.  While specific alterations 
are infrequent, looking at molecular subtypes by dysregulation of overall pathways (e.g. “PI3K-
deficient tumors” as those harboring alterations in PIK3CA, PTEN, or AKT) may identify larger 
subpopulations with susceptibility to targeted treatments. 
Also worth exploring are molecular subtypes that may be not be demarked by a genetic 
alteration but rather a distinct gene expression profile.  For example, TCGA analysis of HGSOC 
identified a group of tumors with an immune-reactive gene signature9.  One could postulate that 
this subgroup of HGSOC may be particularly sensitive to immunotherapy.  Further, we recently 
identified a subset of HGSOC with poor outcome that may be driven by high expression of 
NR4A family members46.  Similarly, estrogen receptor-alpha (ER) is expressed in ~70% of 
epithelial ovarian cancers, most frequently in HGSOC and ENOC subtypes47–49.  Targeting ER 
has been incredibly successful for breast cancer therapy but its potential is under-utilized in 
ovarian cancer. 
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1.2 ESTROGEN IN OVARIAN CANCER PATHOBIOLOGY 
ER is one of two estrogen receptor isoforms, α and β, which are encoded by separate genes on 
separate chromosomes (ESR1 on 6q and ESR2 on 14q, respectively)50,51.  While ERβ expression 
is less prevalent in ovarian tumors52–54, ER is expressed in ~80% HGSOC and ~75% of 
endometrioid ovarian cancer (Fig. 1)49.  Reflecting the diversity of ovarian cancer subtypes 
described above, mucinous and clear cell tumors rarely express ER.   
 
Hormone receptor expression in ovarian cancer carries biologic consequences.  A recent 
study of over 2000 ovarian tumors revealed that while ER is not predictive of survival in 
HGSOC, co-expression of ER and PR portends better disease-specific survival (RR 0.71)49.  In 
endometrioid ovarian cancer, ER alone was prognostic as was ER/PR co-expression (RR 0.41 
and 0.38, respectively).  This finding suggests a specific subset of HGSOC and endometrioid 
ovarian tumors may be hormonally driven.  Importantly, the observation that ER alone is not 
Figure 1: ER expression in ovarian cancer subtypes.  
Percentage of ER+ tumors was graphed based on data 
reported by Sieh and colleagues49. 
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prognostic for survival in HGSOC suggests that while many serous tumors express ER, only a 
subset require it for progression.  Nevertheless, even if only for a small subgroup of patients, 
hormone-dependence in both HGSOC and endometrioid tumors could be exploited 
therapeutically using existing FDA-approved drugs. 
1.2.1 Targeting estrogen receptor in cancer 
Inhibiting ER action (“endocrine therapy”) has proven effective and safe in other malignancies.  
The notion began in the mid-1970s with the discovery of anti-estrogenic effects of tamoxifen.  
Tamoxifen, which originated as a failed contraceptive agent (ICI 46,474), was shown to 
competitively bind the estrogen receptor and, in doing so, inhibit proliferation of breast cancer 
cells55,56.  Numerous clinical studies demonstrating the efficacy and favorable side effect profile 
of tamoxifen led to the establishment of endocrine therapy as the mainstay for breast cancer 
patients with ER+ tumors57.  Three primary modalities of endocrine therapy now exist, each with 
a unique mechanism of action: selective ER modulators (SERMs, e.g. tamoxifen), selective ER 
degraders (SERDs, e.g. fulvestrant), and aromatase inhibitors (AIs, e.g. letrozole). 
 SERMs compete with estrogen for binding to ER58.  The moniker “modulators” reflects 
the fact that the anti-estrogenic effects of SERMs depend on tissue context.  In breast, SERMs 
antagonize ER activity whereas they have agonistic properties in the bone and endometrium59,60.  
Similar to SERMs, SERDs compete with estrogen for binding to ER58.  However, SERDs are 
pure ER antagonists; further, they promote degradation of ER61–63. 
Rather than acting directly on ER, aromatase inhibitors work by reducing estrogen levels.  
Aromatase activity is responsible for conversion of androgens to estrogen in the adrenal glands 
and in peripheral tissues (e.g. adipose) and constitutes the primary source of post-menopausal 
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estrogen64,65.  Further, aromatase expression has been detected in human cancers including breast 
and ovarian, suggesting AIs may work directly on the tumor in addition to decreasing systemic 
estrogen66–68. 
All three classes of endocrine therapy are currently used with success clinically.  In 
addition to being extremely efficacious against hormonally driven malignancies, these therapies 
have very mild side-effect profiles57,64.  Compared to the cytotoxic mainstays of ovarian cancer 
therapy, which come with side effects including nausea, vomiting, alopecia, and leukopenia20,21, 
endocrine therapy produces hot flashes; dizziness; and bone, muscle, or joint pain.  While still 
unpleasant, these side effects provide patients with a much better quality of life comparatively.  
Thus in addition to managing disease burden, endocrine therapy could provide ovarian cancer 
patients with a reprieve from the more debilitating side effects of standard-of-care chemotherapy. 
1.2.2 Estrogen exposure and ovarian cancer risk 
Pointing to an opportunity for endocrine therapy in ovarian cancer are numerous epidemiologic 
studies that link estrogen exposure to ovarian cancer pathogenesis.  Prolonged estrogen exposure 
through nulliparity69,70 and a greater number of menstrual years71,72 has been reported to increase 
risk of ovarian cancer.  Further, oral contraceptive (OC) use has been shown to confer a 
protective effect against epithelial ovarian cancer.  Both prospective and case-control studies 
report ~30% decrease in lifetime ovarian cancer risk with ever-use of OCs70,73,74.  Longer 
duration of use produces greater protection, with an approximate 20% decrease for every five 
years.  Both estrogen and combined estrogen-progestin formulations have protective effects 
although it is debated whether estrogen-progestin formulations provide greater protection than 
estrogen alone.  Presence of a single nucleotide polymorphism (SNP) in CYP19A1, the gene 
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encoding aromatase, has been associated with increased risk of ovarian cancer75.  The SNPs in 
question, rs749292 and rs727479, promote increased aromatase activity (and thus increased 
estradiol levels)75.  Additionally, recent data from patients with ductal carcinoma in situ (DCIS) 
suggests that patients receiving aromatase inhibitory therapy, which decreases estrogen levels, 
have a lower risk of ovarian cancer than those who received tamoxifen76.   
Perhaps suggesting the most causal link between estrogen and ovarian cancer is the 
association of post-menopausal hormone replacement therapy (HRT) use and risk.  To this point, 
a centralized analysis of 52 epidemiologic studies (both prospective and retrospective) reported 
an increased risk of ovarian cancer for ever-users of HRT compared to never-users (RR 1.14 for 
all studies combined)77. Considering just prospective studies, thus eliminating potential 
contamination in control arms, risk was even higher (RR 1.20 for ever-users).  Risk was greatest 
in current users or patients who had used HRT within the last five years (RR 1.37).  Elevated risk 
was almost entirely attributable to increases in risk for high-grade serous (current or recent users 
in prospective studies, RR 1.53) and endometrioid tumors (RR 1.42).  While risk decreased with 
time since last use, prior HRT use of >5 years produced a durable increase in risk. 
This result was recapitulated by two other recent meta-analyses.  These studies also found 
a link between duration of HRT use and ovarian cancer risk, with the greatest risk conferred by 
>10 years of use78,79.  Notably, since the Women’s Health Initiative (WHI) study, HRT use has 
decreased dramatically in the United States; with it, ovarian cancer incidence has decreased 2.4% 
per year80.  Taken together, all of these epidemiologic studies clearly implicate estrogen in the 
etiology of epithelial ovarian cancer. 
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1.2.3 Clinical trials of endocrine therapy in ovarian cancer 
In light of the associations between estrogen exposure and ovarian cancer risk and the frequency 
of ER+ tumors, several clinical trials have evaluated endocrine therapy in ovarian cancer (Table 
2)81–83 and three are ongoing (Table 3: Ongoing trials of endocrine therapy in ovarian cancer).  
Trials have encompassed the three main modalities of anti-estrogen therapy (SERMs, SERDs, 
and AIs).  These trials have been small in cohort size, recruited patients who had been heavily 
pre-treated with chemotherapy, and did not routinely use ER status as inclusion criteria.  
Nevertheless, in each trial a subset of patients received clinical benefit (response or disease 
stabilization) from endocrine therapy. 
 
Table 2: Summary of endocrine therapy trials in ovarian cancer 
Drug Trials (#) Patients (n) ER status Prior chemo regimens 
Response 
(CR or PR) 
Stable 
Disease 
Tamoxifen81,84–94 14 13 - 105 mixed or unknown >1 6 -31% 6-83% 
Aromatase 
Inhibitors81,95–98 7 22 - 54 + or mixed >2 4-17% 50-70% 
Fulvestrant99 1 26 + >2 4% 35% 
 
These trials also indicate that endocrine therapy is effective even in the platinum-resistant 
setting.  Timing of endocrine therapy (e.g. potential earlier introduction as a maintenance 
therapy) could improve response.  Additionally, selection of the appropriate patient population 
will improve response rates.  In breast cancer, expression of ER itself is sufficient to identify 
candidates for endocrine therapy.  In ovarian cancer, however, even the endocrine therapy trials 
that did select for patients with ER+ tumors only saw clinical benefit in a subset of patients. 
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Further, “ER positivity” in ovarian cancer has not been well defined. The cut-offs for 
ER+ are frequently not reported (including in the aforementioned Lancet study) making it 
difficult to interpret associations (or lack thereof) with outcome99,100.  When reported, cut-offs 
for ER+ ovarian tumors vary; for example, one recent study defined ER+ by H-score of >150, 
another used expression above or below the median H-score (90) in the study cohort48,96.  In 
breast cancer, current treatment guidelines from the American Society of Clinical Oncology 
(ASCO) call a tumor ER+ if a histologic tumor specimen contains >1% ER+101.  However, 
emerging data and recent discussions in the literature suggest that breast tumors with weak ER 
expression (1-9% ER+ cells) behave like ER- disease102–104.  Understanding such thresholds will 
be critical to defining the predictive and prognostic role of ER in ovarian cancer.   
 
Table 3: Ongoing trials of endocrine therapy in ovarian cancer 
Trial Drug(s) Lead Investigator Eligible tumors Receptor status Prior rx 
PARAGON Anastrazole  Richard Edmonson, MD 
Epithelial ovarian cancer, 
endometrial cancer, primary 
peritoneal cancer, fallopian 
tube cancer, granulosa cell 
tumor, endometrial 
sarcoma, cervical sarcoma, 
sex cord stromal tumor 
ER+/PR+, 
Epithelial ovarian 
cancer with rising CA-




NCT01273168 Endoxifen  Alice Chen, MD 
Hormone receptor-positive 
breast cancer or other solid 









Progressed on 1+ prior 
standard-of-care rx 
NCT02188550 Letrozole + everolimus  Kenneth Miller, MD 
Relapse, refractory or 
persistent epithelial ovarian 
cancer,, fallopian tube 
cancer, primary peritoneal 





disease or have 




1.2.4 Identifying endocrine-responsive ovarian cancer 
Numerous studies have investigated the link between ER expression and endocrine response in 
ovarian cancer with mixed results.  Two reports identified a significant association between 
quantified ER staining (e.g. AQUA scores) and response to letrozole or fulvestrant105,106.  
However, several other studies found no association86,107,108.  This may be partially attributable to 
the inconsistent definitions of ER positivity discussed above (section 1.2.3) or differences in 
quantitation methods (AQUA score vs. H-score vs. Allred).  Refining the role of ER in 
predicting endocrine response will be critical to selecting appropriate patient populations for 
endocrine therapy.  Equally important will be the implementation of additional biomarkers to 
complement ER expression. 
Three previous efforts have been made to identify biomarkers of endocrine response.  
The first study evaluated 14 estrogen-regulated genes as potential biomarkers of response in 
ovarian cancer patients who received letrozole106.  They found ER targets such as TFF1, PLAU, 
and VIM associated with CA-125 response to letrozole.  In a different study of the same cohort, 
they observed that IGBFP3, IGFBP4, and IGFBP5 associated with response.  A separate report 
found VIM significantly associated with response to fulvestrant105.  However, all of these studies 
looked at short, very focused lists of genes (<10 in a given study).  Larger studies evaluating 
more comprehensive panels of putative biomarkers will be critical to identifying true biomarkers.  
Ideally these would be conducted in a prospective trial setting with pre- and post-treatment tissue 
collection, minimal treatment prior to endocrine therapy, and sufficient ‘n’ to account for a small 
group of responsive patients. 
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1.3 ESTROGEN REPEPTOR SIGNALING IN OVARIAN CANCER 
1.3.1 Overview of estrogen receptor signaling 
Classic ER signaling is stimulated by binding of the ligand, estradiol (E2), to the receptor (Fig. 
2).  Ligand binding produces a conformational change in the protein that facilitates receptor 
dimerization.  Dimerized ER then binds DNA either directly at estrogen response elements 
(EREs) or indirectly through interaction with other transcription factors (e.g. AP1, SP1)109.  
Target genes activated after E2 stimulation vary based on the relative amounts of ER and ERβ, 
which have shared as well as distinct gene targets110.  Targets of both receptor isoforms are 
divided between induced and repressed genes, dependent on the co-regulators recruited111. 
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Co-regulators play a critical role in genomic ER signaling.  Proteins such as SRC-1, 
SRC-2, and SRC-3 are recruited to ER after DNA binding, facilitating interactions between ER 
and general transcriptional machinery to form a larger complex112.  Further, co-regulators can 
function as direct chromatin modifiers (e.g. histone acetyl-transferases) or recruit secondary co-
regulators essential for regulation of gene transcription112–114.  Co-regulators are largely shared 
between the two estrogen receptors (e.g. p160 family proteins, NCOR, SMRT) but some co-
regulators display preferential binding for a given receptor (e.g. RIP140 for ERβ)115.  Moreover, 
Figure 2: Canonical ER signaling. 
Estrogen (E2) is produced by aromatase 
through conversion from testosterone.  
E2 binds ER, promoting receptor 
dimerization.  ER dimers then bind 
DNA to mediate transcription. 
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the balance of co-regulators contributes to the tissue-specific effects of SERMs (e.g. tamoxifen), 
thus carrying significant consequences for endocrine response116–118. 
ER can also be stimulated independent of ligand via direct phosphorylation by kinases 
such as Src, MAPK, and Akt.  Kinases act on S118, S167, and S305, inducing a conformational 
change that allows receptor dimerization and subsequent DNA binding119.  Also suggested has 
been a non-genomic signaling cascade in which ER does not directly mediate transcription but 
rather activates other signaling molecules in the cytoplasm such as MAPK, PI3K, eNOS, SRC, 
and small G-proteins120–122. 
1.3.2 Interplay between ER and PR in ovarian cancer 
Of particular note in ovarian cancer may be the interplay between ER and PR.  PR is a 
canonically estrogen-induced gene and in breast cancer serves as a surrogate for active ER 
signaling123,124.  Further, PR has recently been demonstrated to modulate ER signaling as a direct 
cofactor.  Stimulation of PR by progestins promotes PR binding to ER and redirecting it to 
different sites in the genome125.  
PR is expressed in 31% of HGSOC and 67% ENOC, predominantly in an ER+ 
background49.  Further, PR expression is prognostic for improved survival in HGSOC and 
ENOC126.  This suggests that a subset of ER+ ovarian cancer maintains active ER signaling and 
that these tumors have distinct disease biology.  Further, recent reports suggest that targeting PR 
with synthetic progestins induces senescence in ovarian cancer cells127,128.  Clinical trials of PR 
agonists have produced mixed results (response rates of 0-47%)129–131.  However, this may again 
be due to patient selection given the small percentage of ovarian tumors that express PR. 
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1.3.3 Preclinical studies of ER signaling in ovarian cancer 
Preclinical studies have begun to investigate the role of ER and ERβ in ovarian cancer.  Estrogen 
has been shown to promote proliferation in vitro and modulate expression of known ER target 
genes such as GREB1 in ovarian cancer cell lines and that E2-induced proliferation can be 
blocked by addition of tamoxifen or fulvestrant (ICI 182,780, herein referred to as ICI)106,132,133.  
Further, E2 has been reported to promote ovarian cancer cell migration, in part through ER-
dependent up-regulation of survivin, and to protect cells from anoikis134.  Over-expression of 
ERβ in ovarian cancer cell lines decreased proliferation and negatively regulated ER 
signaling53,135.   Similar to results in the clinic, not all ER+ cell lines require estrogen for 
growth133,136,137.  However, one must interpret cell line results with caution, given reports of 
misidentification of ovarian cancer cell lines (e.g. the widely used BG-1 cell line was identified 
to be MCF-7 breast cancer cells)138.  Additionally, given the heterogeneity of ovarian cancer, 
preclinical results must be interpreted with regard to context of histologic subtype and 
underlying genetic alterations139,140. 
Experiments in animal models have also suggested a role for estrogen in ovarian 
tumorigenesis.  E2 increased tumor growth in PEO1 and PEO4 cell line xenografts132,141.  
Treatment with the aromatase inhibitor letrozole improved survival and decreased tumor 
angiogenesis compared to control-treated animals with OVCAR-3 xenografts142.  In a transgenic 
mouse model driven by SV40-Tag transformation of the ovarian surface epithelium, estrogen 
supplementation did not increase tumor burden but did accelerate the rate of tumor growth143,144.  
Oral contraceptives suppressed spontaneous ovarian tumor development in a hen model145.  A 
transplantable ascites model in Wistar Rats also demonstrated endocrine responsiveness146.  
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Similar to cell line studies, not all animal models have demonstrated endocrine response.  In a 
popular mouse model of endometrioid ovarian cancer, driven by a KrasG12D;Pten-/- transgene, 
treatment with estradiol or the SERM bazedoxifine had no effect on tumor growth134.  
Importantly, endocrine response has yet to be evaluated in patient-derived ovarian cancer 
models. 
While these studies have scratched the surface of endocrine response in ovarian cancer, 
studies of ER downstream signaling are limited.  Early studies focused on expression of known 
ER targets from studies in other cancer types (e.g. FOS, TFF1, cyclins, and IGFBPs)136,147,148.  
Only two large-scale gene expression studies have been conducted to date.  The first was 
performed in PEO1 cells using a 1.2K gene array after 24 hours of E2 treatment and identified 
genes including CYR61, CTSD, and IGFBP3149.  The second utilized a whole-genome 
(Affymetrix U133 Plus 2.0) array to compare expression of PEO4 xenografts treated +/- an E2 
pellet for 11 weeks132.  This analysis identified several known targets of ER including GREB1 
and PGR.  The limitation to both these studies is the duration of treatment.  Due to the long 
exposure of E2, gene expression changes may reflect secondary responses just direct ER targets.  
While secondary responses may be important in E2-driven phenotypes (e.g. proliferation) in 
ovarian cancer, knowledge of direct ER targets will be critical to fully understanding mechanism 
of ER action in ovarian cancer. 
Also important to understanding ER signaling in ovarian cancer will be identifying ER 
co-regulators. Studies to date have largely relied on the assumption that ER activates the same 
target genes and recruits the same co-regulators.  Shared ER target genes between ovarian cancer 
and other malignancies would suggest similar co-regulator profiles.  However, large-scale, 
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unbiased screens such as ChIP-Seq or mass spectrometry will be necessary to determine if 
ovarian cancer cells utilize unique ER cofactors. 
1.3.4 Novel models of ovarian cancer 
The modest improvements in clinical outcomes and limitations of existing cell line models have 
prompted a push for ovarian cancer models that more faithfully recapitulate human malignancy.  
These efforts have focused on the development of genetically engineered mouse models 
(GEMMs), culture of primary ovarian cancer cells, and establishment of patient-derived 
xenografts (PDXs). 
Various ovarian cancer GEMMs have been established over the last almost two decades.  
Many models of HGSOC relied on a traditional view of ovarian tumorigenesis (i.e. restricted to 
the ovary)150,151.   Recently a model recapitulating the evolution of HGSOC from the fallopian 
tube was developed.  Malignant transformation of the fallopian tube secretory epithelium by a 
triple Brca-/-;Tp53R270H/-;Pten-/- transgene produces serous tubal intraepithelial carcinoma (STIC) 
lesions in the fallopian tube which progress into invasive tumors with HGSOC histopathologic 
features and peritoneal metastases152.  Models of endometrioid ovarian cancer have also been 
effectively generated, the most common being a KRasG12D;Pten-/- transgenic153,154.  Most 
recently, a model of clear cell carcinoma7;,however, the model relies on transformation of 
ovarian surface epithelial cells and thus may not accurately reflect clear cell tumorigenesis.  The 
downside of all GEMMs, of course, is that they are models of murine disease and rely on a 
predefined set of drivers.  Thus, they fail to capture the genetic diversity of clinical ovarian 
cancer.  This facet of disease biology is where patient-derived models come into play. 
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Several groups have established banks of ovarian cancer patient-derived xenografts 
(PDXs).  PDXs, which rely on engrafting a piece of patient tumor into an immunocompromised 
host mouse, are currently regarded as the most faithful models of human disease155,156.  Ovarian 
cancer PDXs, when engrafted orthotopically, mimic the intraperitoneal spread and, in some 
cases, significant ascites burden seen clinically157,158.  Further, PDXs often demonstrate the same 
response to therapy observed in patient donors.  In light of this, there are now ongoing clinical 
trials using PDX-guided treatment, including in ovarian cancer (e.g. NCT02312245).  Success of 
such a trial could be a huge boon for ovarian cancer, especially with regard to developing 
personalized treatment strategies. 
A newer system which could also have significant utility is the ex vivo tumor culture or 
“explant” model.  Explant models entail culturing fragments of tumor on a gelatin sponge in a 
culture dish for up to a week159.  This method gained popularity in the prostate cancer field, 
where it has been used to evaluate novel therapeutics against primary tumor tissue159–162.  Unlike 
patient-derived cell lines or xenograft models, which can require months to establish157,158,163, 
explants allow assessment of drug efficacy and pharmacodynamic response within 3-7 days.  
Explants have only been employed once to date in ovarian cancer128.  However, the rapid nature 
and scalability (one small piece of tumor provides sufficient tissue for many replicates or 
treatment groups) of this assay system make it a promising complement to other model systems.  
Further, this model could also permit the assessment of intratumor heterogeneity, which may 
factor into response to targeted therapeutics. 
 21 
1.4 IMPLICATIONS FOR PERSONALIZED THERAPY FOR OVARIAN CANCER  
The heterogeneous nature of ovarian cancer suggests that personalized therapeutic strategies will 
be critical to improving patient outcomes.  Advances in preclinical models of ovarian cancer, 
particularly patient-derived models, have laid the path for ovarian cancer research to make large 
strides forward in this arena   Preclinical and clinical studies suggest that endocrine therapy 
could be an effective strategy in ovarian cancer if the correct patient population can be identified. 
We hypothesized that ER drives ovarian cancer development and progression for a 
subset of tumors and that biomarkers of active ER signaling will identify patients most 
likely to respond to endocrine therapy.  Based on epidemiologic and histopathologic analyses, 
hormone-responsive tumors are most likely to fall into the high-grade serous (HGSOC) and 
endometrioid (ENOC) ovarian cancer subtypes.  In the following chapters, I describe studies to 
understand ER signaling and identify biomarkers of endocrine response across different subtypes 
of ovarian cancer.  I initially study advanced HGSOC, the most common disease subtype, using 
preclinical models and primary patient tissue.  Next I evaluate ER signaling during the 
progression from endometriosis, a hormonally-driven reproductive disease, to endometriosis 
associated ovarian cancers (EAOC).  Finally, I assess the potential role of ER in early-stage 
ovarian tumors of low malignant potential.  Our findings on ER function in epithelial ovarian 
cancer lay the groundwork for future studies of endocrine therapy in ovarian cancer and may 
have significant clinical ramifications for patients. 
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2.0  BIOMARKERS OF ER FUNCTION REFLECT ENDOCRINE RESPONSE IN 
HIGH-GRADE SEROUS OVARIAN CANCER 
2.1 INTRODUCTION 
High-grade serous ovarian cancer (HGSOC), the most common subtype of EOC, is an aggressive 
and often lethal disease with limited options for therapy.  HGSOC patients typically respond to 
surgery and platinum-based chemotherapy as first-line treatment but the majority of patients will 
relapse and ultimately succumb to the disease.  Identifying targeted, individualized treatment 
strategies for ovarian cancer will be essential for improving patient survival. 
One promising but often-overlooked therapeutic strategy for HGSOC is targeting 
estrogen receptor-alpha (ER).  ER is highly expressed in ~80% of HGSOC and estrogen 
exposure (e.g. through oral contraceptive use or post-menopausal hormone replacement therapy) 
affects risk of ovarian cancer49,77,81,164.  In light of these observations, several clinical trials have 
evaluated endocrine therapy in ovarian cancer patients.  Trials have been small, recruited heavily 
pre-treated patients, and did not routinely select patients based on ER status81.  Nevertheless, in 
each trial, a subset of patients benefited from tamoxifen (~20% of patients86), aromatase 
inhibitors (~17%96), or fulvestrant (~40%99).  However, even in trials that selected for patients 
with ER+ tumors, not all patients achieved clinical benefit.  Thus, while endocrine therapy could 
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be successfully used in HGSOC, additional biomarkers are needed to select the appropriate 
patient population. 
We sought to identify ovarian tumors likely to be ER-dependent and responsive to 
endocrine therapy.  To achieve this, we characterized endocrine response with regards to growth, 
survival, and gene expression in HGSOC cell line and patient-derived xenograft (PDX) explant 
models.  Based on our preclinical data, we built a gene signature of endocrine response and 
profiled tissue samples from ovarian cancer patients who received endocrine therapy.  Gene 
expression biomarkers may identify patients who will benefit from therapy. 
2.2 MATERIALS AND METHODS 
2.2.1 Cell culture 
PEO1 and PEO4 cell lines were provided by Dr. Thomas Krivak, who obtained them from HPA 
Cultures UK, and were cultured in DMEM (Invitrogen) + 10% FBS (Gibco).  The OVCA432 
cell line, also provided by Dr. Krivak, was maintained in RPMI-1640 (Invitrogen) + 10% FBS.  
OVSAHO and OVKATE cells were purchased from the Japanese Cell Repository Bank (JCRB) 
and maintained in DMEM + 10% FBS.  CAOV-3 cells were purchased from the American Type 
Culture Collection and maintained in RPMI-1640 + 10% FBS.  MCF-7 cells were cultured in 
DMEM + 10% FBS.  Cells were cultured for <6 months.  Mycoplasma testing was performed 
annually using the MycoAlert kit (Lonza).  Cell line authentication was performed by short 
tandem repeat (STR) profiling. 
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Estradiol (E2) and 4-hydroxytamoxifen (4OHT) were purchased from Sigma (cat. 
#E8875 and #H6278, respectively).  Fulvestrant (ICI182,780; ICI) was purchased from Tocris 
Biosciences (cat. #1047).  E2, 4OHT, and ICI were solubilized in ethanol prior to use in vitro. 
2.2.2 Hormone deprivation 
Cells were hormone-deprived in charcoal stripped serum (CSS) as previously described165.  
Briefly, cells were washed 2X with serum-free, phenol red-free IMEM (Invitrogen #) and then 
put in IMEM + CSS (10% for PEO4, PEO1, OVCA432; 5% for MCF-7, OVSAHO, and 
OVKATE).   Washes were repeated 3-5X per day for 3 days. 
2.2.3 In vitro proliferation and viability assays 
For standard proliferation assays, hormone-deprived cells were seeded in 96-well plates (Fisher 
#353072).  After cells adhered (16-24 hrs), drug was added directly to the wells.  Cell growth 
was analyzed after six days using the FluoReporter dsDNA quantitation kit (Molecular Probes) 
according to the manufacturer’s instructions.  Fluorescence was measured using a VictorX4 plate 
reader (Perkin-Elmer). 
For assays in ultra-low attachment (ULA), cells were treated at the time of seeding and 
relative cell number was measured using the CellTiter-Glo assay (Promega G7573).  Apoptosis 
was measured using the Caspase-Glo 3/7 Assay (Promega G8091).  Luminescence was measured 
on a Promega GloMax plate reader.  For both standard and ULA proliferation/viability assays, 
data are presented as the mean of three to six biological replicates +/- SD.  ULA plates were 
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purchased from Corning (cat #3474).   Data shown are representative of at least two independent 
experiments. 
2.2.4 Cell line gene expression analyses 
For microarray analyses, hormone-deprived PEO4 and PEO1 were plated in biological 
quadruplicates and treated with vehicle, 1 nM E2, 1 µM 4OHT +/- 1 µM E2, or 1 µM ICI +/- E2 
for 3 hours.  Cells were then rinsed with PBS and RNA was isolated using the GE Illustra 
RNAspin mini kit (cat #25-0500-70) according to the manufacturer’s instructions.  RNA quality 
was measured on a bioanalyzer to confirm an RNA integrity number (RIN) of >8.  Gene 
expression was measured on Affymetrix U133A 2.0 arrays.  The CEL files were read and 
expression data RMA normalized the using affy() package in R.  T-tests performed for 5 
comparisons using function limma in R, (E2 vs Vhc, ICI+E2 vs E2, 4OHT+E2 vs E2, 4OHT vs 
Vhc, and ICI vs Vhc).  For each comparison, p-values and fold-changes were obtained for all 
genes.  Significance was determined using a cut-off of p<0.001.  Statistical analysis was 
performed by Soumya Luthra.  Heat maps were generated using the Multiple Experiment Viewer 
(MeV: http://www.tm4.org/mev.html). 
For NanoString analyses, cells were treated with vehicle, 1 nM E2, or 1 nM E2 + 1 μM 
ICI for 8 hours in biological triplicates.  RNA was isolated as described above. NanoString 
nCounter assays were run following the manufacturer’s protocol.  Data were corrected to internal 
positive control probes and then to the geometric mean of five housekeeping genes.  
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2.2.5 Xenograft studies 
All animal studies were approved by the University of Pittsburgh Institutional Animal Care and 
Use Committee.  For PEO4 xenograft studies, C.B.17/IcrHsd-PrkdcscidLystbg-J (SCID/Beige, 
Harlan) mice underwent ovariectomy followed by sub-cutaneous pellet implantation (placebo or 
0.03 mg E2, Innovative Research of America).  Two weeks after surgery, 106 PEO4 cells in 1:1 
RPMI + matrigel were injected intraperitoneally (IP).  Mice were monitored for 11 weeks after 
injection and then sacrificed for tissue harvest.  Tissue was either fixed overnight in 10% neutral-
buffered formalin (NBF) or flash frozen in liquid nitrogen.  Frozen tissue was pulverized using a 
mortar and pestle and then processed for RNA isolation using the Qiagen RNEasy Kit. 
Patient-derived xenografts (PDXs) were provided by Dr. Paul Haluska157.  Fresh 
xenograft tissue was shipped overnight at 4 deg C and, upon arrival, was immediately processed 
for engraftment into SCID/Bg mice (Harlan).  Tissue was processed by mechanical mincing in 
McCoy’s 5A media + 1% anti/anti using surgical scissors.  Minced tumor (0.1-0.2 cc of tissue in 
~0.5 cc McCoy’s) was injected IP using an 18-gauge needle.  To passage PDX tumors, mice 
were sacrificed and necropsies performed in a sterile laminar flow hood.  Tumor tissue was 
harvested from the mouse and processed for re-injection as described above.    
2.2.6 Immunoblots 
Cells were lysed in RIPA (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 
0.5% sodium deoxycholate, 0.1% SDS) with Halt Protease and Phosphatase Inhibitor (Pierce).  
Total protein was quantified using the BCA assay according to the manufacturer’s instructions.  
(Thermo). 
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Twenty (20) micrograms of protein per lane was run on 10% SDS-polyacrlyamide gels 
and transferred to PVDF membranes.  ER levels were evaluated using anti-ER antibody (6F11, 
Leica) and tubulin using (Sigma T6557-.2ML).  Secondary antibodies were obtained from LiCor.  
The blot shown was performed by Dr. Michelle Boisen and is representative of three 
independent experiments. 
2.2.7 Ex vivo cultures for rapid assessment of endocrine response 
PDXs were cultured ex vivo using an established protocol for primary tumors160–162.  Briefly, 
fresh PDX tissue was dissected in HBSS into ~1 mm3 pieces.  Tumor pieces were then 
transferred to 12-well dish.  Each well contained a VetSPON gelatin sponge (Henry Schein, cat. 
#31550) partially submerged in 500 µL of explant media (IMEM + 5% FBS + 10 μg/mL insulin 
+ 10 μg/mL hydrocortisone) + vehicle, 1 μM ICI, or 1 μM 4OHT.  Three pieces of tissue were 
placed on each sponge.  After three days of culture, 30 mg/mL BrdU (Invitrogen #00-0103) was 
added to media 4-6 hours before tissue collection.  Tissue collected for immunohistochemical 
analysis was fixed for ~24 in 10% NBF.  Tissue collected for gene expression analysis was lysed 
in Buffer RLT (Qiagen) + 1% beta-mercaptoethanol, vortexed and passed through an 18-gauge 
needle several times.  RNA was isolated using the RNEasy Mini Kit (Qiagen) according to the 
manufacturer’s protocol.  cDNA conversion and qRT-PCR was performed using Bio-Rad iScript 
and Universal SYBR RT Supermix as according to the manufacturer’s instructions.  Primer 
sequences are listed in Appendix A.  All primers were used at a 200 nM concentration in the 
final reaction mix.  qPCRs were run in a 12-µL reaction volume in 96- or 384-well format using 
Bio-Rad CFX Real-Time Detection Systems.  Immunohistochemical analysis is described below. 
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 For PH045, PH053, and PH070, two sponges per treatment group (six explant pieces 
total) were used for each assay type (i.e. two sponges were set-up for RNA collection and two 
for fixation / eventual IHC).  Two independent experiments were conducted for these three 
models, each experiment using a tumor from an individual mouse.  PH242 was not available for 
a repeat experiment in sufficient time for the preparation of this thesis.   Only one sponge (three 
explant pieces) was used for each treatment group for this model although several time points 
(day 1-3) were assessed. 
2.2.8 Immunohistochemistry 
PDX and explant IHC analysis was performed in the lab.  Tissue sections were deparaffinized in 
a series of xylene washes and rehydrated in ethanol, PBS, and dH2O.  Heat-induced antigen 
retrieval was performed in citrate buffer (pH 6.0) for 30 min using a boiling water bath.  
Endogenous peroxidases were blocked with H2O2 (Dako Peroxidase Block).  Sections were then 
blocked in 5% BSA in PBS + 0.5% Tween-20 for 1 hour at RT.  Sections were incubated in 
primary antibody overnight at 4 deg C. DAKO anti-mouse (K4001) secondary reagent was 
applied for 30 min at RT.  Staining was visualized with 3,3’-diaminobenzidinetrahydrochloride 
(DAB) and slides were counterstained with hematoxylin.  Antibodies are detailed in the table 
below.   
BrdU staining was quantified by determining % Brdu+ cells (# BrdU+ cells / total cells * 
100%) for a given field of view.  For each treatment group, 10 fields of view were counted, 
spanning multiple explant pieces.. 
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Table 4: Antibodies and dilutions for explant/PDX IHC 
Antibody Clone Host Vendor Cat #. Dilution 
ER 6F11 Mouse Leica NCL-L-ER-6F11 1:50 
BrdU Bu20a Mouse Cell Signaling  5292S 1:200 
Ki67 M1B Mouse Dako M724001 1:300 
 
Immunohistochemistry of clinical samples was performed by the research histology core 
at the University of Pittsburgh Medical Center.  Antigen retrieval was performed in citrate buffer 
(pH 6) at 120 deg C.  ER was stained using pre-dilute ER SP-1 clone antibody (Biocare 
Medical).  Staining was detected using Envision Dual Link+ HRP Polymer and DAB (Dako).  
Hematoxylin was used for counterstaining. 
2.2.9 Development of the E2sig and EndoRx panel 
To design a comprehensive assay for estrogen response, we overlapped our microarray results 
with publically available preclinical studies of E2 response in breast, bone, ovarian, and 
endometrial cancer (Appendix B).  Studies were downloaded from the Gene Expression 
Omnibus (GEO) and E2-regulated genes were analyzed by t-test (E2 vs. vehicle) with a cut-off 
of p<0.001.  We also overlapped our data with genes which were differentially expressed 
between ER-positive and ER-negative tumors in The Cancer Genome Atlas (TCGA) breast and 
ovarian cohorts and with genes specific to “hormonally responsive” endometrial cancer (as 
defined by TCGA)9,166,167.  The union of genes from each study type (in vitro, in vivo, and 
TCGA) was taken to determine E2-regulated genes for a given cancer type (e.g. ovary) except 
for breast cancer.  Given the large number of genes identified by the numerous breast cancer 
studies, we used the intersection of these data sets.  E2-regulated genes in each cancer type were 
then compared; this approach identified 207 genes that were estrogen-regulated in at least 3/4 
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cancer types (Fig. 9B).  Ad hoc additions were then made including components of the ER 
signaling axis and genes which correlated with response in clinical trials of endocrine therapy in 
ovarian cancer105,168.  This 236-gene set (the “E2sig”) was validated in silico using the 
METABRIC and Van’t Veer data sets and in vitro by NanoString assays in PEO4 and MCF-7 
cells to confirm estrogen-regulation (Appendix B).  Lastly, we added genes from the literature 
based on associations with endocrine resistance, tumor-stromal interactions, or immune 
response.  The final 350-gene list was named the “EndoRx panel” and is provided in Appendix 
B. 
2.2.10 Analysis of clinical specimens 
Clinical samples were procured from the University of Pittsburgh Medical Center (UPMC), Fox 
Chase Cancer Center (FCCC), Roswell Park Cancer Institute (RPCI), and the University of 
Michigan (Mich).  All clinical samples used contained >50% tumor and >50% viable cells as 
determined by a board-certified pathologist (E.E.). For RNA isolation and subsequent 
NanoString analysis, paraffin sections were scraped off of slides into microcentrifuge tubes.  For 
each sample, four 5-um sections were used.  Samples were deparaffinized using 
Deparaffinization Solution (Qiagen) and processed using the Qiagen AllPrep FFPE RNA / DNA 
isolation kit.  RNA concentrations were measured using the Qubit (Invitrogen) broad range 
protocol.  Gene expression of the EndoRx panel was measured on the NanoString nCounter 
according to the manufacturer’s protocol.  Data were analyzed using nSolver and R.  We 
evaluated potential confounding batch effects between patients at different sites.  Specifically, 
we compared time on endocrine therapy, overall survival, and gene expression (both overall 
patterns and total number of counts).  These analyses are provided in Appendix B. 
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To identify genes associated with endocrine response, patients were stratified into groups 
based on duration of endocrine therapy: “responders” (>120 days on endocrine therapy) and 
“non-responders” (<120 days).  The 120-day cutoff was chosen based on discussions with 
practicing gynecologic oncologists (Drs. Robert Edwards and Michelle Boisen).  Details of the 
statistical analysis are provided below under “Statistical methods.”  Analysis of tissue and 
clinical data was approved by local Institutional Review Boards. 
2.2.11 Statistical methods 
For preclinical studies, significance was determined using a p-value of 0.05 unless otherwise 
specified.  Unpaired, two-tailed t-tests were used for experiments with two groups.  For 
experiments with three or more groups, ANOVA was used followed by Tukey’s post-hoc test. 
For clinical samples, significance of differentially expressed genes was determined by 
likelihood ratio testing followed by Benjamini-Hochberg correction for multiple comparisons.  
Log-rank test was used to determine significance between Kaplan-Meier curves (alpha=0.05). 
2.3 RESULTS 
2.3.1 Endocrine response in HGSOC cell lines 
To determine if estrogen mediated growth in ovarian cancer cells, we evaluated response to E2, 
ICI, and 4OHT in four HGSOC cell lines.  ER was highly expressed in PEO1, PEO4, and 
OVCA432 cells at levels comparable to the hormone-responsive breast cancer cell line MCF-7.  
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Expression was more modest in OVSAHO cells (Fig. 3A).  ERß was not expressed in any of the 
cell lines (not shown).  E2 stimulated proliferation of PEO4 and PEO1 cells in a dose-dependent 
manner.  This was abrogated by treatment with ICI and 4OHT (Fig. 3B), consistent with 
previous reports that E2 can promote ovarian cancer cell growth132,169,170.  In contrast, E2 had no 
effect on proliferation of OVCA432 and OVSAHO cells. 
We next hypothesized that expression of ER target genes (ERTGs) could distinguish ER-
dependent versus -independent HGSOC cells. However, previous studies to identify ERTGs in 
HGSOC are limited132,148   To create a more comprehensive picture of ER signaling and to 
capture primary ERTGs, we performed whole-genome microarrays in PEO4 and PEO1 cells 
after 3-hour treatment with E2, ICI +/- E2, or 4OHT +/- E2.  E2 induced significant (p<0.001) 
gene expression changes in both cell lines (222 genes in PEO1, 293 in PEO4; Fig. 3C, Tables 12 
and 13).  Of these, 94 genes were E2-regulated in both PEO1 and PEO4 cell lines, including 
GREB1, CA12, DEPTOR, GFRA2, OFLM3, and SLC22A5.  E2-regulation of these genes was 
validated by qRT-PCR in independent experiments (Appendix C).  
E2-stimulated changes in gene expression were largely inhibited by ICI and 4OHT.   
Notably, ICI appeared to be more effective in blocking gene expression than 4OHT failed to 
block E2-mediated expression of 101 genes whereas ICI only failed to block 19 in PEO4 cells 
(Fig. 3C).  This is likely attributable to agonistic effects of 4OHT as 4OHT modulated 
expression of several genes independent of E2 (Fig. 3C).  These included genes such as 
BCL2A1, ARID5B, CXCL2, and TXNIP.  However, 4OHT-regulation could not be consistently 
reproduced in independent qRT-PCR experiments (not shown). 
Overlapping our array results with studies of E2-regulated genes in MCF-7 breast cancer 
cells (GEMS data171) revealed conservation of many known ER target genes (ERTGs) including 
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GREB1, MYC, and CCNG2 (Fig. 3D).  IGFBP3, a well-characterized ERTG in HGSOC, was 
E2-repressed in both PEO1 and PEO4 cells but the p-value (0.014) did not reach our cut-off for  
  
Figure 3: Endocrine response in HGSOC cell lines.  A. Expression of ER in HGSOC cell 
lines.  B.  Effect of E2, ICI, and 4OHT on growth of HGSOC cells.  Hormone-deprived cells 
were treated with increasing doses of E2, ICI, or 4OHT.  ICI and 4OHT were added in the 
presence of 100 pM E2.  Data are shown as fold change (FC) vs. vehicle.  Points represent the 
mean of six biological replicates; error bars show standard deviation.  Graphs are representative 
of >2C. Heat maps depicting gene expression changes (log2FC vs. vehicle) after treatment with 
E2 +/- 4OHT,or ICI in PEO4 and PEO1 cells.  Genes shown are significantly regulated by E2 
compared to vehicle (p<0.001).  Microarray analysis was conducted by Soumya Luthra, MS.  D. 
Overlap of E2-regulated genes in PEO1 and PEO4 cells versus MCF7 breast cancer cells (GEMS 
early data).  E. Mean FC (treatment vs. vehicle, three biological replicates) of ERTGs in HGSOC 
cells.  Gene expression was measured by NanoString after 8-hour treatment with Vhc, E2, or E2 
+ ICI.  Error bars show standard deviation of three biological replicates. 
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significance in this experiment.  This is likely attributable to the brief endocrine treatment, which 
enriches for immediate ERTGs.  We were able to confirm its regulation and that of several other 
ERTGs (GREB1, MYC, CCNG2) by qRT-PCR (Fig. 3E).  Expression of these genes was not 
significantly E2-regulated in OVCA432 and OVSAHO cells, consistent with the lack of 
proliferative response (Fig. 3E). 
 
 We then evaluated how E2 affected models of more advanced disease.  To mimic 
ascites, a common clinical manifestation in late-stage HGSOC, we seeded cells in ultra-low 
Figure 4: Endocrine response in an in vitro model of ascites.   A. 
Hormone-deprived cells were plated in ULA  +/- 1 nM E2.  Total ATP 
was measured by CellTiter-Glo assay.  Data are presented as blank-
corrected luminescence (mean of six replicates + standard deviation).  B. 
Hormone-deprived cells were treated with control, E2, ZVAD, or STS.  
Apoptosis was measured using CaspseGlo-3/7 assay.  
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attachment (ULA) plates.  E2 increased viability of PEO1 and PEO4 cells in ULA, similar to 
standard conditions.  Surprisingly, OVSAHO and OVCA432 cells, which were E2-independent 
under standard conditions, became E2-responsive in ULA (Fig. 4A).  We asked if E2 was 
inhibiting anoikis (apoptosis from loss of cell matrix adhesions) in HGSOC cells.  However, we 
saw no effect of E2 on caspase-3/7 activity in ULA (Fig. 4B). 
  In parallel, we assessed estrogen-dependence for PEO4 cells in vivo in mice +/- E2 
pellet supplementation.  E2 treatment increased tumor burden compared to placebo controls (Fig. 
5).  E2 also induced expression of canonical ERTGs (e.g. GREB1, MYC), consistent with in 
vitro studies (Fig. 5).   Xenografts in both conditions expressed high levels of ER (Fig. 5).  Taken 
together, these results suggest endocrine response is context-dependent and can promote features 
of advanced HGSOC. 
Figure 5: Endocrine response in cell line xenografts.  PEO4 cells were injected IP into mice 
after ovariectomy (OVX) plus placebo or E2 pellet supplementation.  Left: Tumor burden was 
measured after 11 weeks and calculated as (tumor weight / total body weight)*100%. Center: E2 
modulates expression of ERTGs in PEO4 xenografts (qRT-PCR). Right: ER IHC in PEO4 
xenografts. 
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2.3.2 Endocrine response in HGSOC patient-derived xenografts 
To examine endocrine response in models more closely mimicking the complex biology of 
HGSOC, we utilized a panel of patient-derived xenograft (PDX) tumors (Tabel 6).  Two of the 
models (PH045 and PH070) were exposed to neoadjuvant chemotherapy.  One patient, the donor 
of PH070, had received previous endocrine therapy for breast cancer.  The overall clinical 
features recapitulate and typical advanced grade and stage (Table 5) of clinical HGSOC.  They 
also recapitulate the varying ER expression (Fig. 6).  However, HGSOC PDXs often take months 
to form detectable tumors157,158, limiting the feasibility of large-scale endocrine response studies 
in vivo.  To circumvent this, we cultured PDX tumor fragments ex vivo as explants172,173 to 
rapidly assess endocrine response (Fig. 7A).   
 
Table 5: Clinical features of patient tumors used for PDX models 
Model Age at dx Stage Grade Subtype Chemo Prior endo rx 
PH045 66 3C 3 serous Neoadj taxol/carbo, doxil, taxotere/carbo no 
PH053 70 3C 3 serous (PP) taxol/carbo no 
PH242 70 4 4 serous taxol/carbo, carbo, doxil, topotecan no 
PH070 62 3C 3 serous Neoadj taxol/carbo AI+Tam for BRCA 
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Figure 6: ER IHC in HGSOC PDXs.  Tumors 
were collected when mice became moribund. (8-
16 weeks after engraftment). 
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Figure 7: Endocrine response in PH045 and PH053 explants.  A. Workflow for explant 
studies.  B & C. ICI and 4OHT treatment decreases proliferation (B) and alters ER target gene 
expression (C) of PH045 explants.  D & E. Effects of ICI and 4OHT treatment on PH053 
explant proliferation and gene expression.  For graphs in C & E, each dot represents an 
individual explant piece.  Bars show mean expression.  Asterisks indicate significance: ****, 
p<0.0001; ***, p<0.001; **, p<0.01; *, p<0.05.  Significance determined by ANOVA. 
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ICI treatment decreased ER levels and reduced BrdU incorporation of PH045 explants 
(Fig. 7B).  The median change in BrdU incorporation after ICI treatment was -50% (range 8% to 
-95%). Decreased proliferation was complemented by repression of ERTGs including GREB1 
and PGR (Fig. 7C).  Similarly, expression of ER-repressed genes CCNG2 and IGFBP3 was 
increased by ICI treatment.  4OHT modestly reduced BrdU incorporation.  While the median 
change vs. vehicle was similar between ICI and 4OHT (-50% vs. -40%), ICI produced a greater 
maximal decrease (95% vs. 58%) and more robust change (p=0.005 vs. p=0.014).  4OHT also 
had less-pronounced effects on gene expression, suggesting ERTGs could be a useful metric of 
drug efficacy.   
ICI and 4OHT also decreased proliferation and gene expression of PH053 (Fig. 7D & 
7E).  Intriguingly, ICI again produced a more significant decrease in proliferation than 4OHT 
(p=0.0049 vs. n.s.).  ICI did not block proliferation or gene expression of PH242 and PH070, 
consistent with these tumors being ER-poor and ER-negative, respectively, in explant culture 
(Fig. 8).  This suggests explant models mimic the variable response to endocrine therapy seen 
clinically. 
We also tried to mimic AI therapy by growing explants in hormone-deprived conditions 
(IMEM + 10% CSS).  However, this produced no significant changes in gene expression relative 
to vehicle / hormone-replete control.  Further, addition of E2 did not produce significant effects 
on gene expression (not shown).  Similarly, there were no significant changes in BrdU 
incorporation between hormone-replete (IMEM + FBS), CSS, or CSS + E2 conditions (not 
shown).  Given that addition of ICI to CSS altered gene expression relative to CSS alone, these 




Figure 8: Endocrine response in PH070 and PH242 
explants. PH070 and PH242 PDX tumors were grown 
as explants.  IHC and gene expression analyses were 
performed after three days of explant culture. 
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2.3.3 Identifying genes associated with clinical endocrine response 
Because modulation of ERTGs corresponded with proliferative response in HGSOC models 
(Figs. 3 & 7), we hypothesized that their expression could predict clinical response to endocrine 
therapy.  To test this, we procured specimens from four medical centers from 70 ovarian cancer 
patients who received endocrine therapy (tamoxifen and/or an AI) (Table 6).  The median age at 
diagnosis was 63 and the majority (85%) of patients presented at late stages (III or IV).  Median 
age at diagnosis was 63 and the majority (85%) of patients presented at late stages (III/IV).  
Patients from RPCI were significantly older (p=0.0009) than patients from the other three sites.  
There was no significant difference in overall survival between patients at different centers 
(Appendix D).  There was also no significant difference in stage, grade, or pre-endocrine therapy 
CA-125 levels, suggesting endocrine therapy was used at a similar point in the disease course at 
each site.. 
Fig. 9A depicts a sample patient timeline.  Upon initiation of endocrine therapy, patients 
are typically maintained on treatment until disease progression.  We had pre- and post-treatment 
CA-125 measurements for 45 / 70 patients; for 41 patients, CA-125 was higher when endocrine 
therapy was stopped (not shown).  Thus, we used duration of endocrine therapy as a surrogate for 
therapeutic response.  There was no association between clinical characteristics (age, stage, and 
grade) and time on endocrine therapy. 
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 Table 6: Clinical features of OVCA patients who received endocrine therapy* 
 
To identify ERTGs and ER regulators critical to endocrine response, we designed the 
EndoRx panel gene signature (see methods, Fig. 9B) and measured expression in tumor 
specimens.  Patients were dichotomized based on duration of endocrine therapy: those who 
received therapy for >4 months were considered “responders” while those treated for <4 months 
were “non-responders.”  Of the various gene sets incorporated into the EndoRx panel, ERTGs 
had some of the strongest associations with endocrine response.  IGFBP3 was significantly lower 
(q=0.015) in patients who responded to endocrine therapy (Fig. 9C).  PGR, MYC, and PDGFRL 
trended towards differential expression (Table 7), with MYC and PGR being elevated and 
PDGFRL being decreased in responders relative to non-responders. 
                                                 
* Descriptive statistics were determined by Tianzhou Ma.  For external sites (RPCI, FCCC, Mich), clinical data were 
provided by the collaborating physician.  
  RPCI (N=20) UPMC (N=17) FCCC (N=9) Mich (N=26) 
Age at dx 72.7 ± 7.3 60.1 ± 9.8 56.8 ± 7.5 59.5 ± 15.0 
Primary/Recur 17/3 17/0 6/3 30/0 
Grade     
Low 0 2 1 3 
High 20 15 8 23 
Stage     
                Early (1-2) 0 1 3 2 
                 Late (3-4) 20 12 6 28 
Pre-endo CA-125 (# censored) 419 ±639 (1) 283 ±503 (6) 463  ±785 (5) 105 ±143 (0) 
Days on endo rx 405 ± 647 383 ± 356 168 ± 115 192 ± 275 
Min 22 38 31 30 
Max 2850 908 396 1470 
Survival after endo rx (days) 687 ± 866 959 ± 641 665 ± 639 628 ± 742 
Overall survival (days) 1961 ± 1361 2497 ±1470 2129±1104 1554 ± 1212 
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Interestingly, ESR1 also trended towards higher expression in responders (q<0.25, 
p=0.003).  Previous attempts to link ER expression with endocrine response in ovarian cancer 
have produced mixed results so we further measured ER by IHC and H-scoring (Fig. 9D).  H-
scores ranged from 0 to 270 (median=60, Fig. 9E).  Surprisingly, ESR1 expression and H-score 
had only a modest correlation (corr=0.41).  However, patients with an H-score above the median 
were more likely to benefit from endocrine therapy (p=0.002, Fig. 9F).   H-score had greater 
predictive power for endocrine response than ESR1 (not shown). 
Finally, we asked how IGFBP3 compared to ER as an indicator of endocrine response.  
To do this, we regressed time on endocrine therapy against IGFBP3 and found it was a better 
discriminator than H-score (p=0.0002 vs p=0.003, Figure 9G).  We then designated patients as 
ERhigh or ERlow (H-score above or below 60, respectively) and IGFBP3high or IGFBP3low (above 
or below third-quartile IGFBP3 expression).  Patients with ERhigh/IGFBP3low tumors had the best 
response to endocrine therapy (Fig. 9H).  While only four patients had ERhigh/IGFBP3high tumors, 
two of them had a dramatically shorter time (<30 days) on endocrine therapy.  Strikingly, 
patients with ERlow/IGFBP3high tumors had significantly worse outcomes than their 
ERlow/IGFBP3low counterparts (Figure 9H, p=0.023).  Patients with ERlow/IGFBP3low tumors had 
outcomes comparable to patients with ERhigh/IGFBP3low tumors, suggesting some ERlow tumors 
retain active ER signaling.  Together, these observations suggest that direct assessment of ER 





Table 7: ERTGs associated with endocrine response in patients. 
Gene logFC p-value q-value 
IGFBP3 -0.8283 9.01E-05 0.0158 
ESR1 0.9252 0.00256 0.227 
PGR 1.1479 0.00726 0.228 
MYC 0.5562 0.00770 0.228 
PDGFRL -0.5322 0.0135 0.257 
  
Figure 9: Identifying ERTGs associated with clinical response to endocrine therapy.  A. 
Timeline of a typical ovarian cancer patient.  After diagnosis (dx), treatment starts with debulking 
surgery and chemotherapy.  Endocrine therapy is typically given after multiple rounds of 
chemotherapy if patients have a “biochemical” recurrence, determined by rising serum CA-125 
levels.  Endocrine therapy is continued until the patients progress by CA-125 or visual evidence of 
disease.  B. Workflow for the design of the EndoRx panel. Meta-analysis was done in 
collaboration with Soumya Luthra and Uma Chandran, PhD.  C. IGFBP3 expression is higher in 
patients who don’t respond to endocrine therapy compared to those who do.  The converse is true 
for ESR1.  Analysis was done by Charles Ma.  D. Representative IHC stains of ER in our patient 
cohort.  E. Distribution of H-scores.  F.  Patients with a higher H-score have better response to 
endocrine therapy. G. Kaplan-Meier analysis of association between IGFBP3 expression and time 
on endocrine therapy.  H. Low IGFBP3 expression identifies subgroups of high- and low-ER 
tumors that are more endocrine responsive. 
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2.4 DISCUSSION 
Clinical trials of endocrine therapy suggest that a specific subset of ovarian cancer patients 
benefits (response or disease stabilization) from endocrine therapy.  However, unlike for breast 
cancer, selecting patients based on ER status (positive vs. negative) is not sufficient to predict 
response in HGSOC.  Implementing biomarkers that complement ER expression will be critical 
to identifying appropriate patient populations for endocrine therapy. 
Three studies have previously tried to identify biomarkers of endocrine response105,106,168.  
These studies all utilized a small panel of IHC markers.  We pursued a comprehensive profile of 
potential biomarkers by designing the EndoRx panel.  Our analysis indicated lower IGFBP3 was 
significantly associated with prolonged endocrine response (Fig. 9).  This corroborates a 
previous report that IGFBP3 immunoscore correlates with response to letrozole106.  IGFBP3 
expression was more strongly associated with endocrine response than H-score (Fig. 9).  Further, 
IGFBP3 expression was able to identify a subgroup of low-ER patients who still benefited from 
endocrine therapy.  Given that IGFBP3 is ER-regulated in HGSOC (Figs 3 & 7, ref. 23), our 
results suggest that a direct output of ER function is a better indication of endocrine 
responsiveness than ER expression alone. 
With the exception of IGFBP3 and TFF1, the latter trending towards an association 
(q<0.3, p=0.023), our analysis did not find strong associations between endocrine response and 
previously reported biomarkers105,106,168.  This could be attributable to differences in 
methodology (gene expression vs. IHC) or cohort size (ours is the largest to date).  Though VIM 
expression was previously shown to be associated with fulvestrant response105, difference in 
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therapy may account for the discrepancy; independent classes of endocrine therapy may require 
different predictive markers. 
Our EndoRx panel was designed based on studies in models that recapitulate the varying 
endocrine response seen in clinical HGSOC.  PEO1 and PEO4 cells were endocrine responsive 
in standard culture conditions whereas OVCA432 and OVSAHO were not.  However, 
OVCA432 and OVSAHO cells became ER-dependent in ULA, suggesting ER has unique roles 
in different stages of ovarian cancer biology.  This observation also emphasizes the necessity of 
translational models such as PDXs or tumor explants to fully understand the role of ER in 
HGSOC. 
We provide the first evidence of endocrine response in patient-derived HGSOC models.  
ICI produced a greater effect on explant gene expression and proliferation than 4OHT, 
suggesting that modality of endocrine therapy will be an important consideration in HGSOC 
therapy.  Selective ER modulators (SERMs, e.g. 4OHT) exhibit partial agonism in certain tissues 
and cancer types165 whereas selective ER degraders (SERDs, e.g. ICI) are pure antagonists.  
Potential tamoxifen agonism in HGSOC has not been explored but tamoxifen was reported to 
promote fallopian tube and ovarian lesions in canines174.  Further comparisons of ICI and 4OHT 
with other SERMs and SERDs will be necessary to understand any differential class effects in 
HGSOC.   
Our explant studies also suggested heterogeneous endocrine response across regions of 
HGSOC tumors: response to both 4OHT and ICI varied in terms of both proliferation and gene 
expression between explant pieces.  It is possible that interactions between different regions 
would allow a response of the tumor in bulk.  However, strategies for combination therapy 
should also be considered.  Two such possibilities are MAPK and Src, which have been shown to 
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crosstalk with ER and drive endocrine resistance in ovarian cancer141.  Co-targeting PGR is also 
promising given its interaction with ER125 and recent reports demonstrating PGR agonists induce 
senescence in ovarian cancer cells125. 
Our analysis is somewhat limited by its retrospective nature.  Modality of endocrine 
therapy and number of previous therapies vary across patients.  Prospective studies with post-
treatment specimen collection, standardized timing of endocrine therapy, and sufficient power to 
compare different endocrine agents will be necessary to solidify the utility of any biomarkers.  
Such future studies could involve a “window trial” of neoadjuvant endocrine therapy, in which 
endocrine therapy is given for a brief period prior to primary debulking surgery and standard-of-
care chemotherapy.  In a window trial setting, pre-treatment specimens could be collected to 
evaluate ER status and expression of putative predictive markers (e.g. IGFBP3); post-treatment 
specimens could be collected at the time of surgical debulking and assessed for 
pharmacodynamic markers (e.g. loss of ER expression for fulvestrant-treated patients, changes in 
ERTG expression compared to untreated tumor) and proliferative markers. 
In summary, ER modulates growth, survival, and gene expression in a subset of HGSOC 
and endocrine-responsiveness is context dependent.  Moreover, targeting ER can be effective in 
patients.  Targeting ER with ICI and 4OHT modulates expression of MYC, PGR, and IGFBP3 in 
preclinical models of HGSOC.  Moreover, expression of these genes reflects clinical endocrine 
response.  Our findings may enable the selection of HGSOC patients who would benefit from 
endocrine therapy.  
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3.0  UNDERSTANDING ER SIGNALING IN OVARIAN CANCER 
3.1 INTRODUCTION 
We and others have described effects of ER on ovarian cancer growth and survival in preclinical 
models (Chapter 2).  However, the mechanisms by which ER executes these effects have not 
been thoroughly elucidated.  To this point, there are only two previous studies of ER-mediated 
transcription (discussed in Chapters 1 and 2) in addition to the study we performed in Chapter 2.  
There are no studies to date evaluating the role of these downstream targets in E2-regulated 
phenotypes in ovarian cancer.  Further, the co-regulators of ER signaling (either classical or non-
genomic) in ovarian cancer have not been well characterized. 
Previous reports have suggested crosstalk between ER and kinase signaling pathways in 
ovarian cancer.  Specifically, Src and MEK have been suggested to directly phosphorylate ER, 
driving ligand-independent activity and endocrine resistance141,175.  In breast cancer, ligand-
independent activation of ER by mTOR/PI3K signaling has been described as a mechanism of 
endocrine resistance176,177 and targeting mTOR in combination with an AI is now an effective 
therapeutic strategy178,179.  Endocrine response can also be affected by crosstalk with cytokine 
signaling (e.g. IL-6/STAT3 pathways)180,181.   
 Herein, we sought to understand the mechanism of ER signaling, with a focus on the 
shift in endocrine responsiveness in OVCA432 and OHSAHO as described above.  We 
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investigated the role of ER target genes in driving E2-mediated growth and survival.  We also 
investigated potential crosstalk between ER and other signaling pathways including IL-
6/STAT3.  Understanding effectors of ER signaling in ovarian cancer will help better identify 
patients with endocrine-responsive tumors and identify possible nodes for combination therapy. 
3.2 MATERIALS AND METHODS 
3.2.1 Cell culture 
PEO1, PEO4, OVSAHO, and OVCA432 cells were cultured and hormone-deprived as described 
in Chapter 2.  Proliferation assays and survival assays were performed with FluoReporter and 
CellTiter-Glo kits as described in Chapter 2.   
E2, 4OHT, and ICI were obtained from Sigma (E2, 4OHT) or Tocris Biosciences (ICI) 
and dissolved in ethanol.  The following inhibitors were purchased from Tocris Biosciences and 
solubilized in sterile DMSO: U1026 (MEK), Saracatinib (Src), LY294002 (PI3K), Stattic 
(STAT3), and Staurosporine (pan-kinase).  OSI-906 (IGF1R/Insulin Receptor inhibitor) was 
purchased from Selleckchem and SNS-314 (AURORAK inhibitor) from ApexBio.  Both were 
solubilized in DMSO.  Recombinant IL-6 was obtained from Life Technologies (#10395-HNAE-
5) and was dissolved in sterile ddH2O prior to use in vitro.   
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3.2.2 Transient knockdown 
Transient knockdown was performed using Dharmacon siRNA smart pools (cat # for DEPTOR 
and # for SLC22A4).  Hormone-deprived cells were reverse transfected with 25 nM siRNA 
using Lipofectamine RNAiMAX (Life Technologies).  RNA was measured by qRT-PCR 48 
hours after transfection.  Cell growth was measured six days after transfection. 
3.2.3 Gene expression analyses in HGSOC cell lines 
For qRT-PCR analyses, RNA was isolated using the GE Illustra RNAspin Mini Kit as described 
in Chapter 2.  Bio-Rad iScript RT Supermix and Universal SYBR Supermix were used for 
cDNA conversion and PCR, respectively.  Primer sequences are listed in Chapter 2 (Table 9).  
Cells seeded in 2-D were treated ~16 hours after plating to allow time to adhere.  Cells seeded in 
ULA were treated immediately after plating.  
For NanoString assays, hormone-deprived cells were treated with vehicle, E2, or E2 + 
ICI for 8 hours as described in Chapter 2.  RNA was isolated as above.  Expression of the E2sig 
was measured on the NanoString nCounter as described in Chapter 2.  
3.2.4 Immunoblots 
Cells were lysed in RIPA as described in Chapter 2.  Cells in 2-D were rinsed with PBS in the 
culture vessel and then scraped in RIPA.  Cells in ULA were collected by centrifugation and 
rinsed with PBS.  The pellet was then lysed in RIPA.  Protein content was quantified by BCA 
assay as described in Chapter 2.  Twenty to thirty (20-30) µg protein per lane was run on 10% 
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SDS polyacrylamide gels and transferred to PVDF membranes.  Blots were imaged using either 
the Olympus LiCor Phosphoimager or chemiluminescence or X-ray film.  The antibodies used 
were: ER (Leica NCL-L-ER-6F11, used at 1:500), pER S118 (clone 16J4, CST #2511, used at 
1:1000), pSTAT3-Y705 (CST, 1:1000), STAT3 (CST, 1:1000), and Tubulin (Sigma, used at 
1:5000).  Secondary antibodies used were either anti-rabbit IgG (CST #7074, used at 1:2000 or 
1:5000) or anti-mouse IgG (Sigma #T6557, used at 1:2000).  Immunoblots for ER in figs. 11 and 
12 were performed by Dr. Michelle Boisen.  The blot in figure 15 was performed by Elizabeth 
Nelson. 
3.3 RESULTS 
3.3.1 Evaluating DEPTOR as a potential mediator of endocrine response 
Through the microarray studies in Chapter 2, we identified DEPTOR as an E2-induced gene in 
HGSOC.  DEPTOR, which is also E2-regulated in breast and endometrial cancers, interacts with 
mTORC1 and 2 to modulate signaling182,183.  Given this observation and known interactions 
between ER and mTOR in other cancer types176,177, we postulated that DEPTOR may contribute 
to E2-stimulated proliferation in ovarian cancer. 
To investigate this, we transfected PEO4 cells with DEPTOR-targeted siRNA and 
measured growth and gene expression after E2 treatment.  After 48 hours, transient knockdown 
completely abrogated E2-stimulated DEPTOR expression (Fig 10).  However, knockdown had 
no effect on E2-induced expression of GREB1, nor did it impact E2-stimulated proliferation in 
2-D (Fig 10).  
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3.3.2 Using changes in ER signaling between 2-D and ULA to identify ERTGs critical to 
growth 
Rather than continue to work through targets identified solely from the microarray, we sought to 
prioritize targets more likely to contribute to E2-driven growth.  Given the shift we observed in 
endocrine response between 2-D and ULA (Chapter 2), we postulated that evaluating ER 
signaling in ULA would help us identify genes and co-factors critical to endocrine response.  In 
light of this, we first compared ER expression between the two conditions.  After 24 hours in 
culture, ER expression was higher for PEO1, PEO4, OVCA432, and OVSAHO cells in ULA 
than in standard culture conditions (Fig. 11).  Similarly, ESR1 mRNA levels increased in ULA 
(Fig. 11), suggesting that higher ER levels in ULA are attributable to elevated transcription.  
 
 
Figure 10: Effects of DEPTOR KD.  A. DEPTOR-targeted siRNA blocks E2-induced 
expression. Gene expression was measured by qRT-PCR 48 hours after reverse transfection and 
24 hours after E2 treatment.  B. DEPTOR knockdown has no effect on E2-induced GREB1 
expression.  Gene expression was measured as in A.  C. DEPTOR knockdown does not affect 2-
D growth.  Proliferation was measured six days after transfection by FluoReporter.  
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To confirm this, we compared ER turnover between 2-D and ULA.  Hormone-deprived 
cells were treated with vhc, E2, ICI, or 4OHT for 4 and 24 hours.  In PEO1 cells, E2 treatment 
led to ER degradation (Fig. 12).  ICI also degraded ER, consistent with its known mechanism of 
action.  Similarly, 4OHT stabilized ER expression.  In PEO4, OVCA432, and OVSAHO cells, 
E2 did not degrade ER but ICI and 4OHT degraded and stabilized ER, respectively (Appendix 
Figure 12: ER degradation in PEO1 cells in 2-D and 
ULA.  Hormone-deprived PEO1 cells were plated in 2-D or 
ULA and treated with vhc, 1 nM E2, 1 µM ICI, or 1 µM 
4OHT.  ER levels were measured by immunoblot after 4 or 
24 hrs.  Blots performed by M. Boisen 
Figure 11:  ER expression in 2-D and ULA. A. ER protein levels measured after 24 
hours in 2-D or ULA (M Boisen).  Representative blot of three independent 
experiments.  B. ER (ESR1) mRNA levels after 24 hours in 2-D or ULA.  Graph shows 
the average of three independent experiments.  Error bars shown standard error of the 
mean.  qRT-PCR was performed by Ravi Patel. 
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E).  Notably, ER turnover did not differ between 2-D and ULA, further indicating that the 
change in ER levels is caused by increased transcription. 
We hypothesized that this increase in ER expression would lead to concomitant increases 
in canonical ER signaling.  To evaluate this, we plated PEO1, PEO4, OVCA432, and OVSAHO 
cells in 2-D or ULA and treated with vehicle, E2, or E2+ICI.  After 8 hours of treatment, we 
collected RNA and evaluated expression of the E2sig (n=236 genes, described in Chapter 2).  As 
expected, E2 treatment induced robust changes in gene expression in PEO1 and PEO4 cells in 
both culture conditions (Fig. 13A).  These were largely abrogated by addition of ICI.  E2 
produced much more modest effects on gene expression in OVCA432 and OVSAHO cells, 
consistent with their lack of endocrine response in 2-D.  Surprisingly, the number of genes 
Figure 13: ER-mediated transcription in 2-D vs. ULA. A. Heat map of E2sig 
expression in HGSOC cells after 8-hour treatment with Vhc, E2, or E2 + ICI.  Heat map 
is colored by log2FC vs. vehicle control (2-D is normalized to 2-D, ULA to ULA). B. 
Percentage of genes on the E2sig significantly E2-regulated in both conditions for each 
cell line. C. Overlap of genes differentially regulated between 2-D and ULA in OVSAHO 
and OVCA432 cells. 
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significantly regulated by E2 did not differ between 2-D and ULA for any cell line (Fig. 13B).  
There were, however, a small subset of genes that exhibited differential E2-regulation between 
2-D and ULA (dashed lines on Fig. 13A, Fig. 13C) in OVCA432 and OVSAHO cells.  Some of 
these genes were repressed in 2-D but induced in ULA.  Others were E2-regulated in the same 
direction but had greater relative FC in ULA.  This latter category included GREB1 and 
SLCC22A4, both of which were more strongly induced by E2 in ULA.  We thus postulated that 
these two genes might contribute to E2-driven growth.   We addressed this by transiently 
knocking down SLC22A4 in several cell lines.  SLC22A4-targeted siRNA decreased expression 
of SLC22A4 but had no effect on growth or survival in ULA (Fig. 14).  This suggests that 
increased induction of SLC22A4 may be a consequence of heightened endocrine responsiveness, 
rather than a mediator of it.  However, other phenotypes (e.g. 2-D growth, anti-estrogen 
Figure 14: Effects of SLC22A4 knockdown on cell growth and survival in ULA.  A. 
Hormone-deprived cells were transiently transfected with scrambled control or SLC22A4-
targeted siRNA and treated with 1 nM E2.  Expression was measured by qRT-PCR 48 hours 
after transfection.  Biological duplicates are shown side by side.  B. Growth in ULA was 
measured by CellTiter-Glo six days after transfection. 
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response) need to be evaluated before SLC22A4 can be ruled out as an effector of ER signaling. 
3.3.3 Identifying pathways that crosstalk with ER 
Overall cellular architecture changes with three-dimensional context (2-D vs. 3-D [matrigel] vs. 
suspension [ULA]).  Thus, our observations regarding the activation of endocrine response in 
low attachment in OVCA432 and OVSAHO cells (Chapter 2) is suggestive of ER crosstalk with 
cell membrane or cytoskeletal cues.  It is likely that ER signaling in ovarian cancer cells is 
mediated in part by interaction with kinase signaling cascades and that targeting these pathways 
may modulate ER function.  To address this, we asked what pathways drive ER-independent 
growth in 2-D.  We screened a small panel of compounds that inhibit MEK, PI3K, IGF1R, 
AURORAK, STAT3, and SRC, respectively against hormone-deprived cells.  Each cell line had 
slightly different sensitivity to inhibitors (Fig. 15).  However, the Src inhibitor Saracatinib 
Figure 15: Small screen of targeted agents in 
HGSOC cells.  Hormone-deprived cells were treated 
with 1 µM of the indicated inhibitor.  Growth in 2-D was 
measured by FluoReporter after six days. 
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partially abrogated growth in all cell lines.  Further, Stattic, an SH2 domain mimetic that inhibits 
STAT3 dimerization184, significantly blocked proliferation in PEO4, OVSAHO, and OVCA432 
cells.  This is consistent with previous reports that STAT3 can drive proliferation in 
HGSOC185,186. 
3.3.4 Evaluating crosstalk between ER and IL-6/STAT signaling 
Given that STAT3 inhibition prevented ER-independent cell growth in multiple cell lines, we 
then compared effects of Stattic in 2-D to those in ULA.  There was no difference in potency or 
maximal efficacy of Stattic between conditions (Fig. 16).  Further, response to Stattic was not 
affected by addition of E2 (Fig. 16).  Despite this, we decided to further investigate potential 
crosstalk between STAT3 and ER signaling based on reports that IL-6-driven STAT3 activity 
can alter endocrine response180,187,188.  Rather than asking if E2 treatment affected STAT3 
inhibition, we asked whether STAT3 activation affected ER activity. 
Figure 16: Effect of Stattic on proliferation of OVCA432 and PEO4 cells.  Cells were 
hormone-deprived and treated with increasing doses of Stattic +/- 1 nM E2.  Growth was 
measured after six days by CellTiter-Glo. 
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Our first approach was to test whether STAT3 activation affected ER-mediated 
transcription.  Thus, PEO1 cells were hormone-deprived and subsequently treated with 
increasing doses of IL-6 or E2 for 24 hours.  Treatment with 10 ng/mL IL-6 significantly 
enhanced E2-induced expression of GREB1 and DEPTOR in PEO1 cells (Fig 17A).  In light of 
this, we expected that IL-6 stimulation would enhance E2-stimulated growth in HGSOC cells.  
However, IL-6 had no effect on E2-stimulated proliferation of PEO1 cells in 2-D (Fig. 17B).  We 
also hypothesized that IL-6 mediated STAT3 induction led to increased activation of ER.  To 
Figure 17: Potential crosstalk between IL-6/STAT3 and ER in HGSOC. A. Effects of IL-6 
treatment on E2-mediated gene expression.  Hormone-deprived PEO1 cells were treated with 
increasing doses of E2 or IL-6 as indicated.  Gene expression was measured by qRT-PCR 24 
hours after treatment.  B. Effects of IL-6 on E2-stimulated growth.  PEO1 cells were hormone-
deprived and treated with increasing concentrations of E2 +/- 10 ng/mL IL-6.  Growth was 
measured by FluoReporter after six days.  C. Effects of IL-6 on ER phosphorylation.  Cells were 
treated with 1 nM E2, 10 ng/mL IL-6, or the combination for 1 or 18 hours as indicated. 
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evaluate this, we measured phosphorylation of ER at S118.  Cells were hormone-deprived and 
treated with vhc, E2, IL-6, or the combination for 1 or 18 hours.  IL-6 treatment induced STAT3 
phosphorylation and had no effect on ER phosphorylation (Fig. 17C).  However, we have not yet 
evaluated the effect of IL-6 on other phosphorylation sites (e.g. S167) or on E2-mediated growth 
in ULA.  It is possible that ER and IL-6/STAT3 crosstalk in these contexts. 
3.4 DISCUSSION 
The heterogeneous response to endocrine therapy in ovarian cancer imparts a need to understand 
mediators of ER signaling as both biomarkers of response and potential nodes for combination 
therapy.  In Chapter 2, we described identification of ERTGs that reflected active ER signaling.  
Herein, we sought to understand how these target genes and other potential effectors (e.g. kinase 
signaling cascades) affected E2-driven growth and survival in HGSOC. 
Endocrine response in HGSOC cells changes based on three-dimensional context, 
specifically in ultra-low attachment versus adherent conditions (Chapter 2).  This corresponded 
with increased ER levels in ULA compared to 2-D.  This was due to upregulation of ESR1 at the 
mRNA level.  We postulated that increased ER expression would lead to increased ER 
transcriptional activity, which would help us identify drivers of E2-driven proliferation.  
Surprisingly, we observed very few changes in E2-regulated gene expression between 2-D and 
ULA, even in OVCA432 and OVSAHO cells.  Among those were GREB1 and SLC22A4.  
GREB1 is required for ER-mediated proliferation in MCF-7 cells and has recently been 
identified as a co-factor for ER188–190.  Thus, one could speculate that GREB1 has the same role 
in HGSOC.  SLC22A4 is a solute carrier and has been implicated in chemotherapy 
 60 
resistance191,192.  While SLC22A4 knockdown had no effect on E2-stimulated growth in ULA, 
we did not evaluate how it affected response to ICI or 4OHT.  Importantly, our phenotypic 
studies were limited to growth assays in ULA.  Characterizing the effects of SLC22A4 
knockdown on other phenotypes (e.g. 2-D growth, spheroid formation, in vivo growth, potency 
of E2 [EC50]) will be critical before ruling out a role for it in endocrine responsiveness.  
Additionally, we did not evaluate the role of GREB1. This should be an avenue for future study. 
The context-dependent change in endocrine response also suggests that ER may interact 
with the cell membrane or with cytoplasmic signaling components.  To assess this potential 
signaling, we performed a small screen of targeted agents in hormone-deprived cells.  This 
screen suggested that inhibiting STAT3 completely abrogates E2-independent growth in HGSOC 
cells.  Further, STAT3 inhibition blocked growth equally well in the presence of E2.  The 
dependence on STAT3 was intriguing because STAT3 activation has been demonstrated into 
induce tamoxifen resistance in ovarian cancer cell lines181.  IL-6 stimulation, which leads to 
phosphorylation of STAT3, enhanced ER-induced expression of GREB1 and DEPTOR.  IL-6 
treatment alone had no effect on expression of either gene, suggesting IL-6 treatment is 
somehow modulating ER signaling.  However, IL-6 treatment had no effect on ER 
phosphorylation at S118.  IL-6/STAT3 pathway activation could have stimulated ER 
phosphorylation at an alternative site (e.g. S167, S305) and this should be investigated further.  
Moreover, lack of changes in ER phosphorylation does not rule out the possibility that these two 
signaling pathways could be interacting at the DNA-binding level.  To this point, STAT3 has 
been previously shown to modulate GREB1 expression in MCF-7 cells188.  Additional studies 
such as ChIP re-ChIP assays would help determine if STAT3 is recruited to the same DNA 
binding sites as ER upon co-stimulation with E2 and IL-6.  Further, RNA-seq analysis after 
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treatment with E2, IL-6, or the combination could identify additional genes that are 
synergistically regulated by E2 and IL-6.  Notably, however, co-stimulation did not affect E2-
driven proliferation in 2-D.  Future studies should first evaluate effect of IL-6 on other E2-driven 
phenotypes such as growth in ULA before delving into mechanistic analyses. 
Our inhibitor screen identified several other pathways that may interact with ER in 
HGSOC cells as well and thus could be possible targets for combination therapy.  Notably, 
Saracatinib, which inhibits Src, was very effective at blocking growth of OVCA432 cells and 
partially inhibited growth of PEO4 and OVSAHO cells.  Src has been reported to promote 
fulvestrant resistance in PEO1 cells via direct interaction with ER, which leads to its 
sequestration in the cytoplasm141.  Future studies should expand upon potential interplay between 
Src and ER and the role of Src as a driver of endocrine resistance.  Additionally, experiments 
such as reverse phase protein arrays (RPPA) will provide more insight into potential drivers of 
E2-independent growth in HGSOC and create a comprehensive picture of changes in ER 
signaling in different contexts.  Similarly, ER localization should be evaluated after treatment 
with E2, ICI, or 4OHT in both 2-D and ULA.  
Another important area of future investigation is estrogen metabolism.  Several groups 
have reported expression of aromatase, which produces estradiol, in epithelial ovarian tumors193–
196.  Further, estrone sulfatase activity has been detected in advanced stage ovarian tumors and 
correlated with worse outcome197.  Intratumor estrogen metabolism could have significant 
implications for endocrine therapy.  One could speculate that tumors expressing steroidogenic 
enzymes may be more hormonally driven.  Alternatively, ovarian tumors lacking steroidogenic 
enzymes or the enzymes necessary to convert estrone into the more potent ligand estradiol may 
be less endocrine responsive.  Future studies should investigate expression and activity of 
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enzymes such as aromatase, estrone sulfotransferase, and steroid sulphatase in clinical 
specimens.  Further, expression and activity of these enzymes should be compared across 
preclinical models to assess their potential contributions to endocrine responsiveness. 
In summary, we determined that IL-6/STAT3 activation might interact with ER 
signaling; however, the phenotypic consequences of this crosstalk remain unclear.  Larger-scale 
studies such as RNA-seq and RPPA will be necessary to fully understand this crosstalk and 
elucidate other effectors of endocrine response and resistance in HGSOC. 
 
 63 
4.0  EVOLUTION OF ESTROGEN SIGNALING IN THE PROGRESSION FROM 
ENDOMETRIOSIS TO ENDOMETRIOSIS-ASSOCIATED OVARIAN CANCER 
4.1 INTRODUCTION 
Endometriosis is a common condition, affecting 6-10% of women of reproductive age and 35-
50% of women with infertility198,199.  It is defined as presence of endometrial glands at extra-
uterine sites, frequently in the pelvis199.  While endometriosis is regarded largely as a benign 
condition, endometriotic lesions can undergo transformation to specific subtypes of invasive 
ovarian cancer16,200.  Illustrating this, a pooled analysis of case-control studies revealed odds 
ratios of 3.05, 2.11, and 2.04 for the development of clear cell (CCC), endometrioid (ENOC), 
and low-grade serous ovarian cancers for patients with a self-reported history of endometriosis 
compared to those without201.  Further, approximately 60-80% of CCC and ENOCs present in 
the setting of atypical endometriosis.  As such, these subtypes are often referred to as 
endometriosis-associated ovarian cancers (EAOC).  However, the mechanisms underlying the 
progression from endometriosis to EAOC are poorly understood. 
Identifying biomarkers and pathways associated with the transition from endometriosis to 
cancer is an active area of research.  Recent reports have identified differences in microRNAs 
profiles between healthy patients, those with endometriosis, and those with EAOC202.  
Immunologic pathways, particularly the complement cascade, have also been implicated as a 
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factor in the transformation from endometriosis to EAOC203.  One pathway that has been 
understudied to date, however, is estrogen signaling 
Estrogen is a known driver of endometriosis, contributing to both proliferation of the 
ectopic uterine tissue and inflammatory response199,204.  Hormonal therapy (e.g. estrogen-
progestin contraceptives or GnRH agonists) is typically prescribed to regulate proliferation of 
endometriotic implants199.  Estrogen has also been implicated in ovarian cancer progression (e.g. 
through hormone-replacement therapy use, discussed in Chapter 1.0), particularly for the 
endometrioid subtype.  Taken together, these clinical observations suggest that estrogen may 
contribute to progression of endometriosis to EAOC. 
Here we investigate estrogen signaling during the progression of endometriosis into 
EAOC using a cohort of tissue samples from healthy controls, patients with both benign and 
atypical endometriosis, patients with endometriosis diagnosed concurrently with ovarian cancer, 
and patients with EAOC. Using a comprehensive gene signature of estrogen response (the 
E2sig), we identified gene expression changes associated with each disease state.  Understanding 
changes in estrogen signaling during disease progression will help determine if ER is a putative 
driver of transformation from endometriosis to EAOC. 
4.2 MATERIALS AND METHODS 
4.2.1 Clinical specimens 
Clinical specimens were shared with us by Dr. Anda Vlad’s lab.  Tissue samples were obtained 
from patients at the University of Pittsburgh Medical Center undergoing pelvic surgery for 
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indications including fibroids, pelvic pain, endometriosis, pelvic mass, and confirmed or 
suspected ovarian malignancy.  Tissue inclusion was contingent upon adequate samples of 
benign endometriosis, atypical endometriosis, endometriosis within the vicinity of an EAOC 
collected at the time of primary surgery (referred to herein as “concurrent endometriosis”), or 
endometriosis-associated cancers (clear cell or endometrioid ovarian cancer) as determined by a 
pathologist (E.E.).  “Concurrent” cancers were defined as any epithelial ovarian cancer with 
endometriosis identified within the pathologic specimen following surgical resection. Dr. Vlad’s 
lab also procured samples of normal endometrium from patients without a diagnosis of 
endometriosis or cancer to use as controls.  All tissue samples underwent an independent 
pathology review by a staff pathologist prior to inclusion in this study.  Corresponding patient 
demographic characteristics, clinical disease characteristics, and treatment factors were 
abstracted from patient charts.  All work was approved by the Institutional Review Board (IRB) 
at the University of Pittsburgh. 
4.2.2 RNA extraction and NanoString analysis 
FFPE sections were processed using the RNEasy FFPE Kit (Qiagen) by Dr. Swati Suryawanshi 
according to the manufacturer’s instructions.  Expression of the E2sig (described in Chapter 2) 
was measured using a custom code set for the NanoString nCounter platform.  RNA (100 ng) 
was prepared for NanoString analysis according to the manufacturer’s protocol.  Data were 
normalized to internal positive controls and to the geometric mean of five housekeeping genes.  
Additional details of the analysis are provided below under “statistical analysis.” 
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4.2.3 Immunohistochemistry 
Immunohistochemistry (IHC) for both ER (SP-1 clone) and FGF18 (Sigma, used at 1:500) was 
performed by the Department of Pathology at Magee-Womens Hospital of the University of 
Pittsburgh Medical Center.  Stained slides were then reviewed and scored by a staff pathologist 
(E.E.).  ER staining was quantified by H-scoring. 
4.2.4 Statistical analysis 
Gene expression for each sample was normalized to the mean expression of that gene in the 
normal endometrium.  To identify genes differentially expressed across the four tissue types, we 
performed ANOVA with a significance cut-off of q<0.05.  The 158 genes identified by ANOVA 
were used for the remaining statistical analysis. 
For comparisons to preclinical profiles of hormone receptor signaling, we utilized 
publicly available data from the Gene Expression Omnibus (GEO).  For ER signaling, we used 
the following studies: GSE50695, GSE3529, GSE22600, and GSE38234.  For ERβ signaling we 
used GSE1153 and GSE42347; for PR, GSE46715.  Hormonally regulated genes were classified 
as those significantly altered by treatment compared to vehicle control.  The heat map show log2 
fold change (hormone vs. vehicle).  Statistical analysis was performed by Tianzhou (Charles) 
Ma. 
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4.2.5 Gene set enrichment analysis (GSEA) 
GSEA was performed by Dr. Matthew Sikora.  To evaluate signatures similar to the E2sig, all 
236 genes were overlapped against gene sets in the C2 (curated gene set) collection of the 
molecular signatures database (MsigDB).  To identify gene signatures activated in EAOC, up-
regulated and down-regulated in EAOC relative to normal endometrium were compared to a 
cancer-specific subset of gene sets in MsigDB C2.  Up-regulated genes comprised those in 
clusters 1 and 2 (Fig. 18); down-regulated genes were those in clusters 3 and 4. 
4.3 RESULTS 
4.3.1 Identification of differentially expressed genes between normal, endometriosis, and 
cancer tissues 
We evaluated 83 samples from patients with benign endometriosis (n=19), which includes both 
ovarian (n=11) and non-ovarian endometriosis (n=8); atypical endometriosis (n=11); concurrent 
endometriosis (n=9); and EAOCs (n=21).  Also included were 23 samples of normal 
endometrium with an equal distribution between the proliferative and secretory phases.  The 
sociodemographic and disease characteristics of this patient cohort are summarized in Table 8.  
Not surprisingly, the patients with concurrent endometriosis and EAOC were older than those 
with benign and atypical endometriosis (median age of 70 and 57.5 versus 39 and 47 years old, 
respectively). The majority of patients with EAOC presented at an early stage (15 patients, 71%) 
and had tumors of endometrioid and clear cell histologies (14, 66% and 5, 24% respectively).  
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The majority of patients with endometriosis were premenopausal while the majority of patients 
with EAOC were postmenopausal at the time of surgery.   
To profile estrogen signaling in patient samples, we analyzed expression of the E2sig.  
The E2sig is a 236-gene panel genes identified by a meta-analysis of estrogen-regulated genes 
across breast, ovarian, endometrial, and bone cancer (described in Chapter 2.2.9). 
 
Table 8: Overview of patients with endometriosis or EAOC† 









Median age (range) 39 (25-74) 47 (34-50) 70 (49-75) 57.5 (47-77) 
Body mass index 27.6 30.6 27.4 29.6 
Menopausal status   
Premenopausal 10 7 2 2 
Postmenopausal 1 1 3 11 
Unknown 8 3 3 8 
Cancer stage N/A N/A (concurrent)  
Early (I-II)    15 (71%) 
Late (III-IV)    6 (29%) 
Tumor histology N/A N/A (concurrent)   
Clear Cell    5 (24%) 
Endometrioid    14 (66%) 
Serous    1 (5%) 
Adenocarcinoma NOS    1 (5%) 
 
Given the discrepancy in age between endometriosis and cancer patients, we first 
evaluated if expression of the E2sig changed based on menopausal status.  To do this, we 
compared expression of the entire gene set across samples from normal endometrium.  Pre-
menopausal and post-menopausal patients did not cluster separately (Appendix F).  Further, a t-
                                                 
† Clinical data were compiled by Dr. Michelle Boisen and Dr. Swati Suryawanshi 
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test comparison identified no genes significantly different between these two groups.  Thus, any 
changes observed in expression are likely due to differences in tissue biology rather than 
hormonal status of the patient. 
We next evaluated how estrogen signaling changes during the progression from benign 
endometriosis to EAOC.  ANOVA identified 158 genes with significantly different (q<0.05) 
expression between different disease states and these genes separated into four distinct clusters 
(Fig. 18A).  Expression of genes in cluster 1 (C1, n=37) is higher endometriosis specimens 
compared to normal endometrium and highest in EAOC (e.g. FGF18, ESR2).  Cluster 2 (C2, 
n=60) represents genes that are highly expressed in the EAOC specimens compared to all 
endometriosis specimens and includes MUC1, PAX8, TP53, and NRIP1.  Cluster 3 (C3, n=20) 
Figure 18: Differentially expressed genes between endometriosis and EAOC. A. ANOVA 
identified 158 genes of the E2sig with significantly (q<0.05) different expression between 
normal endometrium, endometriosis, and endometriosis-associated cancers.  Unsupervised 
clustering reveals four distinct gene clusters.  B. Average expression of gene clusters across 
tissue types.  Differential expression analysis was performed by Tianzhou Ma. 
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comprises genes that are more highly expressed in endometriosis tissue than in the EAOC and 
includes IGFBP4 and FOS.  The final cluster (C4, n=41) consists of genes that are expressed at 
lower levels in both endometriosis and EAOC than in normal endometrium and includes 
GREB1, ESR1, and PGR.  The full list of genes in each cluster is provided in Appendix F. 
4.3.2 Changes in hormone receptor expression and canonical ER signaling in EAOC 
The ANOVA results identified significant changes in expression of the hormone receptors ER 
(ESR1), ERβ (ESR2), and progesterone receptor (PGR).  Expression of ESR2 increases 
incrementally from normal endometriosis to EAOC (Fig. 19).  Conversely, PGR expression 
decreases from normal endometriosis to EAOC.  ESR1 expression is decreased in benign and 
atypical endometriosis but increases again in EAOC. 
We further investigated ER expression by immunohistochemistry.  This also suggested a 
decrease from benign endometriosis to EAOC (Fig. 20); median H-score decreased in intensity 
from normal endometrium to benign endometriosis to EAOC and had a modest but significant 




Figure 20: ER H-scores in endometriosis and
EAOC. ER expression in clinical samples was
evaluated by IHC and H-scoring.  H-scoring
was performed by Dr. Esther Elishaev. 
Figure 19: Hormone receptor expression in endometriosis and EAOC.
Expression of ESR1, ESR2, and PGR as measured by NanoString. 
 72 
We next asked if gene expression patterns in EAOC represented active ER signaling.  To 
do this, we compared expression of the 158 differentially expressed (DE) genes to four gene 
expression studies of estrogen treatment in breast cancer cell lines, ovarian cancer cell lines, and 
endometrial cancer cell lines132,165,205,206.  We also included one study of gene expression in 
MCF7 breast cancer cells performed in our lab (Appendix B).  This comparison revealed that 
some components of canonical ER signaling are maintained in EAOC (Fig. 21), including high 
expression of NRIP1.  However, much of canonical gene regulation is deactivated, as indicated 
by the decrease of GREB1 and PGR.  The same analysis was performed comparing our cohort to 
profiles of ERβ and PGR signaling; no similarities were found between our data and these 




 Since the preclinical studies in GEO specifically represent activated ER in cancer, we 
performed Gene Set Enrichment analysis (GSEA) against the Molecular Signatures Database 
(MSigDB) to evaluate ER signaling in a more unbiased manner (Fig.21).  GSEA identified 
Figure 21: Expression profiles of endometriosis and EAOC tissues compared to ER 
signaling in preclinical cancer models.  Gene expression of our cohort was compared to 
expression data from five studies following estrogen treatment in breast cancer 
(GSE50695, GSE3529, Andersen), ovarian cancer (GSE22600), and endometrial cancer 
(GSE28234) cell lines.  Cell line studies are colored by FC of E2 treatment vs. vehicle 
control, patient samples FC vs. normal.  Analysis was performed by Tianzhou Ma. 
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extensive overlap with ER signaling signatures, consistent with the signature design.  Despite 
this initial enrichment, however, GSEA did not identify any activated ER-related signatures 
among genes over-expressed in EAOC compared to normal endometrium.  Conversely, among 
under-expressed genes in EAOC vs. normal endometrium, GSEA identified signatures related to 
endocrine resistance and loss of ER function where these genes were similarly under-expressed. 
These observations suggest that, consistent with decreased ER expression, EAOC inactivate 
canonical ER signaling, and may actively transition to an ER-independent phenotype.  
 
4.3.3 High expression of FGF18 in EAOC 
Given this shift in ER signaling, genes most highly expressed in EAOC (C1 and C2) likely 
represent de-repressed ER targets.  To this point, among genes in cluster C2 is IGFBP3, which is 
Figure 22: Consort diagram for GSEA. A. Genes from the E2-signature were overlapped 
against gene sets in the C2 collection (irrespective of expression changes). B. GSEA was 
performed using a focused subset of the C2 collection (see Methods); multiple comparisons 
corrections were omitted due to the small size of the gene list.  GSEA was performed by Dr. 
M. Sikora. 
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a known ER-repressed target in ovarian cancer168.  De-repression of these genes may impact 
tumorigenesis; for example, FGF18 (cluster 1) overexpression has recently been identified as a 
poor prognostic marker in HGS ovarian cancer208.  FGF18 also modulates migration and 
invasion of ovarian cancer cells208.  In our cohort, FGF18 mRNA expression increased with 
increasing malignancy of the disease state (Fig, 23).  In light of these observations, we further 
investigated expression of FGF18 in EAOCs by immunohistochemistry.  FGF18 was highly 
expressed in a subset of EAOCs (Fig. 23).  Given its demonstrated role in HGSOC and elevated 
expression in EAOC, de-repression of FGF18 may promote EAOC progression. 
 
Figure 23: FGF18 expression in endometriosis and EAOC. A. FGF18 
expression across different tissue types. B. Representative staining of 
FGF18 in EAOC samples. 
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4.4 DISCUSSION 
Endometriosis and ovarian cancer are both estrogen-responsive disease entities.  Given this 
shared pathway, we investigated how ER signaling evolves during progression from 
endometriosis to EAOC by profiling a comprehensive signature of estrogen-regulated genes in 
patient tissue.  Surprisingly, our results indicate that canonical ER signaling is largely inactivated 
during the progression from endometriosis to EAOC; rather, gene expression in EAOC mirrors 
profiles of estrogen resistance.   
The overall loss of canonical ER signaling in the transition from endometriosis to EAOC 
has not previously been reported.  However, this notion is supported by several studies of the 
complex interplay between hormone receptors in endometriosis.  ER and PR levels have been 
shown to be significantly lower in endometriosis compared to normal endometrium while ERβ 
was elevated209.  Further, ERβ was reported to regulate ER in endometriosis-derived stromal 
cells210,211.  Knockdown of ERβ in endometriotic stromal cells resulted in increased ER mRNA 
and protein levels while ERβ overexpression in endometrial stromal cells led to decreased ER.  
This is particularly intriguing in light of our observation that ESR2 mRNA levels are elevated in 
EAOC compared to normal endometrium.  ERβ is generally thought to be anti-proliferative and 
to antagonize pro-proliferative effects of ER212–215.  However, this may be dependent on tissue 
context.  To this point, a study in endometriosis-derived stromal cells reported treatment with E2 
significantly increased the proportion of cells in S-phase, which was blocked by siRNA 
knockdown of ERβ211.  This suggests that estrogen regulates proliferation in endometriosis 
through activation of ERβ rather than ER.  Further supporting this notion is a recent report of 
increased ERβ activity in a mouse model of endometriosis.  This elevated ERβ activity led to 
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decreased apoptosis and increased proliferation in ectopic endometriotic lesions209.  One could 
postulate that a shift from ER to ERβ signaling could factor into transformation from 
endometriosis to EAOC.  This would be consistent with our finding that canonical ER signaling 
is largely deactivated in EAOC. 
Inactivation of canonical ER signaling is reflected by the decrease in genes such as 
GREB1, IGFBP4, and PGR.  Loss of PR could carry significant consequences for proliferation 
of these tissues as progesterone signaling abrogates estrogen-induced proliferation of normal 
endometrium.  In addition, progestins have been suggested to have an anti-inflammatory role in 
the endometrium. In light of this and a recent finding that inflammation factors into progression 
from endometriosis to EAOC203, there may be significant overlap between the hormonal 
regulation and inflammatory regulation of disease progression.  Indeed, targeting ER with 
ligands that also decreased inflammation was shown to block progression of endometriosis in a 
preclinical model204.  The interplay between estrogen signaling and inflammation in 
transformation of endometriosis to EAOC should be a focus of future study, 
While components of canonical ER signaling were decreased in EAOC, there was a 
subset of ER-induced genes that remained highly expressed in EAOC (e.g. NRIP1).  NRIP1, 
which encodes for RIP140, is a nuclear receptor co-regulator.  RIP140 has been previously 
shown to interact with both ERβ and ER in ovarian cancer cell lines to promote proliferation135.  
This observation suggests that activation of these genes despite down-regulation of ER could 
promote transformation to EAOC. 
Another possibility based on the shift in ER signaling is that de-repression of ER target 
genes promotes EAOC growth and the development of endocrine resistance.  Supporting this 
notion is the increased expression of FGF18 in EAOC.  FGF18 is estrogen-repressed in our 
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HGSOC models (Appendix F) and has previously been described as a driver of tumorigenesis 
and poor prognostic marker in HGSOC208.  Our results further support a role for FGF18 as a 
driver of ovarian tumorigenesis.   
Potential interplay between the ERs and FGF18 in the development of EAOCs has not 
been described in the literature.  However, broader FGFR signaling has been implicated in 
endocrine resistance in breast cancer165,216–219.  Future investigations should focus on 
understanding crosstalk between FGF18 and the ERs and on the potential of FGF18 as both a 
biomarker and therapeutic target. 
A limitation of our analyses is that the small cohort of EAOCs did not provide enough 
power to compare clear cell carcinomas to endometrioid tumors.  Previous reports have indicated 
that only 6% of clear cell tumors express ER and PR, whereas the majority (63%) of 
endometrioid tumors express both receptors49,220.  Further endometrioid tumors are reported to 
have higher expression of ERβ than clear cell tumors221.  One could postulate that these two 
histologic subtypes may diverge in their hormone response.  However, larger cohorts will be 
necessary to compare differences in ER signaling between the two groups. 
In summary, expression profiles of primary tissue samples suggest ER expression and 
classical signaling decreases during the progression of endometriosis to EAOC.  Several ER-
induced genes remain highly expressed in EAOC (e.g. NRIP1) and may contribute to estrogen-
dependent EAOC progression.  Similarly, de-repression of ER target genes such as FGF18 may 
facilitate the transformation of endometriosis into EAOC. 
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5.0  HORMONE RECEPTOR EXPRESSION AND SIGNALING IN OVARIAN 
TUMORS OF LOW MALIGNANT POTENTIAL 
5.1 INTRODUCTION 
Ovarian tumors of low malignant potential (LMP), or borderline tumors, are a unique entity 
defined by atypical epithelial proliferation without stromal invasion6. They comprise 
approximately 15% of all epithelial ovarian tumors and, similar to invasive ovarian cancer, are 
sub-classified by histology222.  LMP ovarian tumors carry a favorable with approximately 70% 
being diagnosed at stage I and a 5-year overall survival of greater than 90%223.  However, almost 
20% of these patients will be diagnosed under the age of 40 and thus fertility conservation 
becomes a critical consideration during surgical counseling222. 
The primary treatment for LMP tumors is surgical resection.  The recurrence risk is 6-
36% depending on stage at time of original diagnosis, extent of surgical resection and certain 
high-risk pathologic features224–227.  Recurrent tumors are treated again by surgical resection 
because these tumors are largely unresponsive to cytotoxic chemotherapy228.  In the same vein, 
adjuvant chemotherapy does not improve progression-free or overall survival for those 
diagnosed with more advanced disease229. 
Currently, the ability of LMP tumors to undergo malignant transformation is 
undetermined.  LMP tumors do not constitute a distinct precursor or preinvasive lesion; however, 
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when patients recur, they can present with secondary LMPs or with invasive tumors.  Given that 
cytotoxic chemotherapy has little effect on late stage and non-resectable recurrent disease, new 
strategies for adjuvant therapy are needed to prevent recurrence. 
Epidemiologic data suggest a role for steroid hormones in the etiology of LMP tumors, as 
has been previously noted for invasive ovarian cancer (described in Chapter 1).  Increasing parity 
and lactation have been reported to correlate with a reduced risk of LMP tumors230; conversely, 
unopposed estrogen use and obesity correlated with an increased risk of tumor development.  
Further corroborating this is a recent study demonstrating that >60% of serous LMP tumors 
demonstrate ER expression and >80% express PR48.  Studies of endocrine response in ovarian 
cancer have primarily been conducted with models of invasive ovarian cancer; however, there 
may still be a role for steroid hormones in the development of ovarian LMP tumors, particularly 
given the expression of ER and PR.  If LMPs have active hormone signaling, they may be 
treatable with adjuvant endocrine therapy.  The objective of the work herein was to investigate 
the role of hormone receptors in ovarian LMP tumors. 
5.2 MATERIALS AND METHODS 
5.2.1 Clinical specimens 
FFPE tissue samples were procured from patients with ovarian tumors of low malignant potential 
treated at the University of Pittsburgh Medical Center from 1990-2010.  All specimens were 
obtained from the Health Sciences Tissue Bank at Magee-Womens Hospital of UPMC.  Samples 
were reviewed by a board-certified pathologist to ensure accurate diagnosis and tissue quality for 
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subsequent molecular analysis.  Clinicopathologic data was abstracted from medical charts by 
Dr. Sarah Taylor.  All studies were approved by the University of Pittsburgh Institutional Review 
Board (IRB). 
5.2.2 Immunohistochemistry 
Immunohistochemistry was performed by the Department of Pathology at the Magee-Womens 
Hospital of UPMC.  Tissue sections were stained with Ventana CONFRIM anti-ER (SP1), 
CONFIRM anti-PR (1E2), and ERβ (AbD Serotec) antibodies. ER and PR 
immunohistochemistry (IHC) was performed using the Ventana BenchMark ULTRA IHC 
staining module as described by the provider (Ventana Medical Systems, Inc., Tucson, AZ).  
ERβ-1 was stained using protocol described by Stabile et al.231.  Briefly, tissue sections were 
deparaffinized and placed in dH2O.  Diva antigen retrieval was performed (Biocare Medical).  
Slides were cooled and rinsed in dH2O, endogenous peroxidase quenched with 3% H2O2 and 
slides placed in working TBS. Slides were incubated with CAS Block (Invitrogen) then with 
working primary antibody. Slides were washed in TBS buffer, incubated with Mach4 Universal 
Probe (Biocare Medical). Slides were washed with TBS buffer, incubated with Dako Substrate 
Chromagen, rinsed in ddH2O and counterstained and dehydrated.  Normal ovarian tissue, normal 
cervical tissue, and invasive breast carcinoma tissue were used as positive controls for ERβ.  H-
scoring for ER was performed by Dr. Rohit Barghava.  Tumors were considered positive or 
negative for a given hormone receptor based on the following scores: <50, negative; 51-100, 
weak positive; 101-200, intermediate positive; >200, strong positive. 
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5.2.3 RNA isolation and NanoString assays 
RNA was isolated by Dr. Sarah Taylor from FFPE cores using Qiagen RNeasy Mini Kit.  Gene 
expression of the E2sig was performed using the NanoString nCounter platform as described in 
Chapter 2.   
5.2.4 Statistical Analysis 
NanoString data were corrected for an internal positive control and then normalized to the 
geometric mean of five housekeeping genes using nSolver.  Unsupervised hierarchical clustering 
of NanoString data was performed using the Multiple Experiment Viewer (MeV) to identify 
genes differentially regulated between serous and mucinous LMPs.  To determine which of these 
differences were statistically significant, we used a non-parametric t-test followed by a 
Bonferroni adjustment for multiple comparisons with a cut-off of p<0.01. 
5.3 RESULTS 
5.3.1 Hormone receptor expression in LMP tumors 
Thirty-eight patients were included in this study.  Median age at diagnosis was 37.5 (range 18-
69).  Twenty-six (68.4%) underwent surgical staging at the time of primary surgery.  Notably, 
over half (52.6%) of these patients underwent fertility sparing surgery at the time of initial 
surgical resection.  All patients had stage I disease.  The histological subtypes were divided 
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between 20 serous and 18 mucinous tumors.  Average length of follow-up was 48 months (range 
1-124).  At time of last follow-up, all patients except one were alive.  That one patient passed 
away from recurrent, progressive cervical cancer.  Four patients (10.5%) had recurrences during 
clinical follow-up. 
We first evaluated expression of ER, ERβ, and PR by immunohistochemistry and H-
scoring (Fig. 24).  The median H-score for ER was 135 (range 0-295), ERβ was 20 (0-120), and 
PR was 85 (range 0-265).  When separated by histologic subtype median H-score for the serous 
subtype was 257.5 for ER (range 90-295), 30 for ERβ (0-120), and 175 for PR (range 15-265).  
The median H-score for the mucinous subtype was 0 for ER (range 0-150), 0 for ERβ (0-40), and 
0 for PR (range 0-170).  Based on these scores, all of the serous tumors were ER and PR positive 
and six of 20 (30%) were ERβ positive.  Only one of the 18 mucinous tumors (5.6%) was 
positive for both ER and PR; all of the mucinous samples were negative for ERβ.  
Figure 24: Hormone receptor expression in ovarian LMP tumors.  A. H-scores of hormone 
receptors in serous and mucinous LMPs (determined by Dr. R Bharghava). B. Representative 
staining of ER and PGR in serous LMPs. 
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5.3.2 Analysis of ER signaling in LMPs 
Based on the differential staining patterns noted between the serous and mucinous subtypes, we 
sought to better understand hormone receptor expression patterns at the RNA level as well as 
downstream signaling.  To accomplish this, we analyzed mRNA expression of ER, ERβ, PR, and 
he E2sig (Chapter 2).  From the NanoString analysis, ERα and ERβ mRNA expression was 
found to be mutually exclusive.  ERβ mRNA levels were elevated in the mucinous LMP tumors 
and ERα mRNA expression higher in the serous samples (Fig. 25).  We further compared protein 
expression to mRNA expression.  Overall ER protein expression, represented by H-scores, 
correlated strongly with ER mRNA expression (r2=0.5606, Fig. 26).  PR protein expression 
correlated with PR mRNA expression (r2=0.42), even when examined by histologic subtype, 
serous (r2=0.74) and mucinous (r2=0.59) (data not shown).  However, ERβ expression did not 




Figure 26: Correlation of ER mRNA and H-score.  ER 
H-score was plotted against the normalized NanoString 
counts for ESR1 and fit to a linear regression.  Solid line 
shows the best-fit regression and dashed lines show the 
95% confidence interval. 
Figure 25: ESR1 and ESR2 are mutually exclusive in 
LMPs.  NanoString data of ESR1 and ESR2 expression 
in LMP tumors.  Blue dots represent serous tumors and 
black dots represent mucinous. 
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Hierarchical clustering of all of the genes in the E2sig revealed a clear separation of 
serous from mucinous subtypes (Fig. 27).  Notably, expression of canonical ER-induced genes 
(e.g. GREB1, DEPDC6) was higher in the serous subtypes while expression of the co-regulators, 
(NCOAs and NCORs) was higher in the mucinous subtypes.   Upon further investigation, 44 
genes showed a statistically significant difference (p<0.01) between the serous and mucinous 
subtypes.  Genes higher in the mucinous tumors included PRLR, PRKCD, and TMPRSS2.  
Genes higher in serous tumors included ESR1, FGF18, and ARL4C.  
Figure 27: Differentially expressed genes 
between serous and mucinous LMPs. T-tests 
followed by Bonferroni correction identified genes 
in the E2sig with significantly different expression 
between serous and mucinous LMPs. 
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5.4 DISCUSSION 
Ovarian tumors of low malignant potential are a unique entity that lack an invasive component 
but have the capacity to recur and possibly become invasive.  Given that 70% of these tumors 
were diagnosed as stage I disease, it is not surprising that all of the samples in this study fell into 
this category.  However, even with this early stage of diagnosis, four patients (10.5%) were 
noted to have recurrence of disease during their follow-up.  Frequently, these tumors are 
amenable to surgical resection at the time of recurrence.  However, LMP tumors exhibit a poor 
response to chemotherapy, limiting options to treat recurrent disease, which may not be 
amenable to resection, or advanced stage LMP tumors with high risk of recurrence.  Thus, new 
strategies for adjuvant treatment are critically needed. 
Previous case reports have shown that LMP tumors can be successfully treated with 
endocrine therapy.  Additionally, a phase II study of letrozole reported a response rate of 30% in 
13 patients with advanced or recurrent low-grade serous carcinoma and low malignant potential 
tumors232 and this response correlated with ER/PR status of the tumors.  These data suggest that 
endocrine therapy can be effectively used in the LMP tumor setting.  However, a critical step in 
implementing such a regimen will be prospectively defining the appropriate patient population.  
Previous reports on hormone receptor expression in LMP tumors suggest that serous and 
endometrioid subtypes express ER and PR and in turn might benefit from hormonal therapy.  In 
our study, we investigated expression of ER, ERβ, and PR at both the mRNA and protein level.  
Further, we evaluated ER function by measuring expression of the E2sig.   
We found high levels of ER and PR expression in serous LMPs and high expression of 
downstream ER targets (e.g. GREB1), suggesting that these tumors may have active hormone 
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signaling.  Interestingly, mucinous tumors had significantly higher levels of ERβ mRNA but this 
did not correlate with high levels of ERβ protein expression when examined by IHC.  This 
finding is intriguing and should be validated by staining with an additional ERβ antibody.  If 
reproducible, this discrepancy could be attributable to post-transcriptional and translational 
modification and should be an area of future investigation233,234.  In light of the contrasting, 
hormone receptor expression, it was surprising that mucinous tumors expressed higher levels of 
NCOAs and NCORs than serous LMPs.  However, we did not assess expression of other nuclear 
receptors (e.g. androgen receptor, glucocorticoid receptor) which may still be involved in 
mucinous tumor biology. 
Given that mucinous tumors largely did not express ER or PR, the striking differences in 
gene expression (shown by discrete clustering of serous and mucinous tumors) suggest that this 
separation is likely more attributable to underlying lineage differences between the two 
histologies rather than differences in estrogen signaling.  Additional large-scale analyses (e.g. 
genome-wide RNA-seq, RPPA) are warranted to better understand the differences between these 
two subtypes and identify avenues for targeted therapy in mucinous LMPs. 
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6.0  DISCUSSION 
Ovarian cancer is a rare but often-fatal disease comprised of multiple unique subtypes.  To date, 
ovarian cancer treatment paradigms have been driven by a ‘one-size-fits-all’ strategy that regards 
the different histologic types as one unified disease.  However, the lack of improvements in 
patient outcomes over the last four decades235 and the low response rates to targeted therapies 
suggest a critical need to implement more personalized strategies. 
 An often-overlooked strategy for ovarian cancer treatment is targeting ER through 
endocrine therapy.  Endocrine therapy is well-tolerated in patients, has been a tremendous 
success in breast cancer, and can also be effective in ovarian cancer, indicated by preclinical 
studies and clinical trials (discussed in Chapters 1 and 2).  However, identification of the 
appropriate ovarian cancer patient population is paramount to its clinical success.  Unlike in 
breast cancer, ER status alone has not proven sufficient to predict endocrine response in ovarian 
cancer; thus, additional biomarkers are needed. 
Our findings suggest that outputs of ER function (e.g. ERTG expression) can be 
harnessed to identify hormonally responsive ovarian tumors.  Implementation of such biomarkers 
in the clinic could identify patients who are likely to respond to endocrine therapy and ultimately 
have profound results for ovarian cancer patients.  If prospective trials based on our risk score or 
other biomarkers were successful, this could produce a paradigm shift in ovarian cancer 
treatment.   
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Biomarker-driven trials will be challenging, however, given the rarity of the disease (9.4 
cases in per 100,000 women for the disease in total236), particularly for non-HGSOC tumors.  To 
organize trials of sufficient size and power will require coordination across multiple centers, 
likely through efforts of cooperative groups such as the Gynecologic Oncology Group. 
An important consideration for investigations of endocrine therapy in ovarian cancer will 
be comparisons of different drug classes.  Reports that tamoxifen exposure is associated with 
lesions in the fallopian tube and ovary174,237, greater efficacy of ICI versus 4OHT in explant 
studies (Chapter 2), and the observation that AIs confer less risk for ovarian cancer in ductal 
carcinoma in situ patients than tamoxifen76, particular attention should be given to efficacy of 
SERMs versus other endocrine agents.   
An additional consideration for the implementation of endocrine therapy is that 
intratumor heterogeneity will require endocrine therapy to be combined with another agent to 
completely abrogate tumor growth.  Further, even if endocrine therapy is successful as a single 
agent, one could envision the emergence of endocrine resistance as is seen in breast cancer238,239.  
Future studies should investigate the mechanism(s) of ER signaling, specifically with regard to 
crosstalk with other pathways (e.g. STAT3).  Effectors and co-factors for ER will identify 
putative targets for combination treatment with endocrine therapy.  Importantly, these studies 
should be performed and interpreted in subtype-specific contexts. 
Such studies will require a more thorough characterization of endocrine response in 
EAOC and LMP tumors.  To date, such studies have been limited by a paucity of representative 
preclinical models for these disease subtypes.  This could be partially alleviated by use of explant 
models.  We derived the explant models for our studies from PDX tumors (Chapter 2) but these 
could also be derived from primary patient tissue. 
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Explants provide a unique opportunity to study ER signaling in epithelial ovarian cancer.  
In addition to serving as a platform to evaluate for drug efficacy, explant models could be used to 
characterize ER signaling in a more clinically relevant setting.  Advances in technology (e.g. 
RNA-seq, ChIP-Seq, and SILAC) now allow profiling of the transcriptome, cistrome, and 
proteome from small tissue inputs.  This renders these analyses amenable to smaller culture 
systems such as explants, enabling the rapid evaluation of signaling in primary tissue. 
In summary, endocrine therapy is a promising treatment strategy for epithelial ovarian 
cancer.  The studies herein describe identification of a risk score for ER activity in HGSOC, 
changes in ER signaling during development of ENOC and CCC, and expression of ER and 
downstream canonical targets in LMP tumors.  These studies lay the groundwork for future 
preclinical investigations of ER signaling in ovarian cancer, which will be enhanced by more 
sophisticated technologies and disease models.  Further, prospective clinical trials taking into 
consideration markers of ER function may observe better response rates than those which did not 
use any biomarkers as inclusion criteria.  Ultimately, such work may facilitate the use of 




Primer sequences for studies in Chapter 2 and 3 are provided in the table below. 
 
Table 9: Primer sequences 
Gene Forward (5’->3’) Reverse (5’->3’) 
RPLP0 TAAACCCTGCGTGGCAATC TTGTCTGCTCCCACAATGAAA 
GREB1 GGTTCTTGCCAGATGACAATGG CTTGGGTTGAGTGGTCAGTTTC 
ESR1 GAGTATGATCCTACCAGACCCTTC CCTGATCATGGAGGGTCAAATC 
IGFBP3 CACAGATACCCAGAACTTCTCC CAGGTGATTCAGTGTGTCTTCC 
CCNG2 GTTTGGATCGTTTCAAGGCG CCTCTCCACAACTCATATCTTCAC 
PGR TCGCCTTAGAAAGTGCTGTC GCTTGGCTTTCATTTGGAACG 
MYC GCTGCTTAGACGCTGGATTT GAGTCGTAGTCGAGGTCATAGT 
DEPTOR TTGTGGTGCGAGGAAGTAAG CCGTTGACAGAGACGACAAA 





ENDORX PANEL NANOSTRING CODE SET 
This appendix provides additional details on the EndoRx panel, which encompasses the E2sig.  
Genes in the E2sig were identified by a meta-analysis of E2-regulated genes in breast, ovarian, 
endometrial, and bone cancer (described in section 2.2.9).  The lists of studies are provided 
below.  Data from GEO were downloaded, processed, and analyzed by Soumya Luthra and Dr. 
Uma Chandran. 
Table 10: Studies used in the E2sig. 
Tissue GEO DataSet 
GEO accession 
OR 1st author Platform Samples used 
Bone GDS884 GSE1153 Affy U95A 
U2OS-Era vhc 1+2, U2OS-ERa E2 4h 
1+2, U2OS-ERa E2 8h 1+2, U2OS ERa 
E2 24h 1+2 
Bone GDS1094 GSE2292 Affy Human HG Focus Target 
ERa Cont A-F, ERab Cont A-F, ERa E2 
A-D, ERab E2 A-E 
Bone GSE21769 GSE21769 Illumina humanWG-6 
U2OS_ERa_doxy_rep1-3, 
U2OS_doxyE2_rep1-3 




Bone NA Hartmaier Affy Human Gene 1.0 ST all 
Breast GSE1045 GSE1045 Affy U133A 
WT control A+B, MDA-MB-231 
expressing WT ER 1 hr A+B, MDA-
MB-231 expressing WT ER 2hr A+B 
Breast GDS3285 GSE11324 Affy U133 Plus 2.0  all 
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Breast GDS3217 GSE11352 Affy U133 Plus 2.0 
12hr untreated control rep1-3, 12hr E2-
treated rep1-3, 24hr untreated rep1-3, 
24hr E2-treated rep1-3 
Breast GDS3283 GSE11506 Affy U133 Plus 2.0 all 
Breast GDS1873 GSE2225 Affy U133A control rep 1-3, estrogen treated rep1-3 
Breast GSE26834 GSE26834 Affy U133A 2.0 
SFM control (3hr) rep1-2, E2-treated 
(3hr) rep1-3, SFM control (24hr) rep 1-
3, E2-treated (24hr) rep1-3 
Breast GDS1549 GSE3529 Affy U133A all 
Breast GDS2770 GSE4006 Affy U133A Ad+veh rep1+2, Ad+E2 rep1+2 
Breast GDS2367 GSE4025 Affy U133A Ad+veh rep1+2, Ad+E2 rep1-3 
Breast GDS3105 GSE6800 Affy U133 Plus 2.0 24h_DMSO_1+2, 24h_Estradiol_1+2 
Breast GDS881 GSE848 Affy HG U95A control A+B, E2 8h A+B 
Breast GDS3315 GSE8597 Affy U133 Plus 2.0 MCF7_EtOH_24_rep-14, MCF7_E2_24h_rep1-4 
Breast GSE3834 GSE3834 Affy U133A and U133A Plus 2.0 All 
Breast NA NA Affy U133A 2.0 TCGA 
Endometrial  GSE38234 GSE38234 Illumina HiSeq 2000 
T47D_DMSO_R1+2, T47D_E2_R1+2, 
ECC1_DMSO_R1+2, ECC1_E2_R1+2 
Endometrial GDS3604 GSE3013 Affy U95A v 2 
EECs from stage I control, Eecs from 
stage I estrogen, EEC from stage II 
control, EEC from stage II estrogen -- no 
replicates 
Endometrial  NA  NA Affy U133A 2.0 TCGA 
Endometrial   GSE3762  GSE3762 MRC Human Known Gene Oligo 
24h E2 & control -- control data 
available through ArrayXpress: 
http://www.ebi.ac.uk/arrayexpress/exper
iments/E-GEOD-3762 
Ovary GSE22600 GSE22600 Affy U133A 2.0 All 
Ovary NA Andersen Affy U133A 2.0 3h E2 and 3H Vhc 
Ovary NA NA Affy U133A 2.0 TCGA 
 
The design of the EndoRx panel is described Chapter 2.  Table 11 lists all of the genes in the 
panel and their associated groupings.  Selection of the genes in the E2sig is described above.  
The “endocrine rx” genes were chosen by literature searches for genes associated with endocrine 
response and resistance.  “Immune” genes were chosen based on known roles in immune 
response.  The last set of genes in the code set, “tumor/stroma interactions (McLean GOIs)”, 
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were added at the request of our collaborator Dr. Karen McLean based on her research interest in 
the microenvironment and its effect on endocrine therapy response.  
 
Table 11: Genes in the EndoRx NanoString code set 
No. Gene Annotation 
1 ABAT E2sig 
2 ADM E2sig 
3 AKAP1 E2sig 
4 ALDH3A2 E2sig 
5 ARHGAP26 E2sig 
6 ARID1A E2sig 
7 ARID5B E2sig 
8 ARL4C E2sig 
9 ARNTL E2sig 
10 ASB13 E2sig 
11 ASCL1 E2sig 
12 ATP2A3 E2sig 
13 BCAR3 E2sig 
14 BCL2L11 E2sig 
15 BICD1 E2sig 
16 BMP7 E2sig 
17 C19orf6 E2sig 
18 C1orf116 E2sig 
19 C20orf160 E2sig 
20 C5orf13 E2sig 
21 C6orf89 E2sig 
22 CA12 E2sig 
23 CA8 E2sig 
24 CALD1 E2sig 
25 CAMK2D E2sig 
26 CAMSAP1 E2sig 
27 CBY1 E2sig 
28 CCNG2 E2sig 
29 CDC25A E2sig 
30 CDCA7 E2sig 
31 CDK6 E2sig 
32 CEP68 E2sig 
33 CGNL1 E2sig 
34 CHN2 E2sig 
35 CISH E2sig 
36 CITED2 E2sig 
37 CLASP2 E2sig 
38 COCH E2sig 
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39 CPD E2sig 
40 CTSC E2sig 
41 CUEDC1 E2sig 
42 CYB561 E2sig 
43 CYP26B1 E2sig 
44 CYR61 E2sig 
45 DAAM1 E2sig 
46 DEPDC6 E2sig 
47 DHRS3 E2sig 
48 DKK1 E2sig 
49 DNAJB4 E2sig 
50 DTL E2sig 
51 DUSP1 E2sig 
52 EGFR E2sig 
53 EHF E2sig 
54 ENPP5 E2sig 
55 EPHA4 E2sig 
56 ESR1 E2sig 
57 ESR2 E2sig 
58 EZR E2sig 
59 FAM174B E2sig 
60 FAM46C E2sig 
61 FBXO32 E2sig 
62 FGF18 E2sig 
63 FJX1 E2sig 
64 FLVCR2 E2sig 
65 FOS E2sig 
66 FOXA1 E2sig 
67 FZD6 E2sig 
68 GALNT10 E2sig 
69 GALNT4 E2sig 
70 GAS6 E2sig 
71 GATA3 E2sig 
72 GCLM E2sig 
73 GFRA2 E2sig 
74 GINS2 E2sig 
75 GNAS E2sig 
76 GREB1 E2sig 
77 GSN E2sig 
78 HELLS E2sig 
79 HIP1 E2sig 
80 HNF1B E2sig 
81 HOXD3 E2sig 
82 ID2 E2sig 
83 IFNAR2 E2sig 
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84 IGFBP3 E2sig 
85 IGFBP4 E2sig 
86 IGFBP5 E2sig 
87 IL12A E2sig 
88 IL24 E2sig 
89 INPP4A E2sig 
90 INPP4B E2sig 
91 ITGB4 E2sig 
92 ITPK1 E2sig 
93 KIAA1217 E2sig 
94 KIAA1467 E2sig 
95 KLF5 E2sig 
96 KRT4 E2sig 
97 LEF1 E2sig 
98 LIFR E2sig 
99 LIMK2 E2sig 
100 LONRF2 E2sig 
101 LRP8 E2sig 
102 MARCKS E2sig 
103 MBOAT1 E2sig 
104 MCM10 E2sig 
105 MDN1 E2sig 
106 MLPH E2sig 
107 MPP7 E2sig 
108 MPPED2 E2sig 
109 MPZL2 E2sig 
110 MTUS1 E2sig 
111 MUC1 E2sig 
112 MXD4 E2sig 
113 MYB E2sig 
114 MYBL1 E2sig 
115 MYC E2sig 
116 MYLIP E2sig 
117 NCF2 E2sig 
118 NCOA1 E2sig 
119 NCOA2 E2sig 
120 NCOA3 E2sig 
121 NCOR1 E2sig 
122 NCOR2 E2sig 
123 NETO2 E2sig 
124 NFIA E2sig 
125 NFIB E2sig 
126 NRIP1 E2sig 
127 NXT1 E2sig 
128 OLFM1 E2sig 
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129 OLFML3 E2sig 
130 ONECUT2 E2sig 
131 OSBPL11 E2sig 
132 OSBPL3 E2sig 
133 OTUB2 E2sig 
134 PAX8 E2sig 
135 PCDH7 E2sig 
136 PDGFRL E2sig 
137 PDK3 E2sig 
138 PDZK1 E2sig 
139 PGR E2sig 
140 PHLDA1 E2sig 
141 PKIB E2sig 
142 PKNOX2 E2sig 
143 PKP2 E2sig 
144 PLAU E2sig 
145 PLOD2 E2sig 
146 PODXL E2sig 
147 POLR3E E2sig 
148 PPAT E2sig 
149 PPP1R3C E2sig 
150 PRKCD E2sig 
151 PRLR E2sig 
152 PSD3 E2sig 
153 PTPRE E2sig 
154 PTPRH E2sig 
155 PVT1 E2sig 
156 RAB17 E2sig 
157 RAI14 E2sig 
158 RARA E2sig 
159 RASGRP1 E2sig 
160 RBBP8 E2sig 
161 RCAN3 E2sig 
162 RDX E2sig 
163 REPS2 E2sig 
164 RHOBTB3 E2sig 
165 RHOF E2sig 
166 RHOQ E2sig 
167 RIF1 E2sig 
168 RND3 E2sig 
169 RNF144A E2sig 
170 RNF19A E2sig 
171 RNF213 E2sig 
172 RNF41 E2sig 
173 SAMD4A E2sig 
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174 SARDH E2sig 
175 SCD E2sig 
176 SEC14L2 E2sig 
177 SEMA3B E2sig 
178 SHB E2sig 
179 SIX1 E2sig 
180 SLC22A4 E2sig 
181 SLC22A5 E2sig 
182 SLC25A29 E2sig 
183 SLC2A1 E2sig 
184 SLC30A1 E2sig 
185 SLC35A3 E2sig 
186 SLC35F2 E2sig 
187 SLC39A14 E2sig 
188 SLC7A2 E2sig 
189 SLC7A5 E2sig 
190 SLC7A6 E2sig 
191 SLC9A3R1 E2sig 
192 SMTNL2 E2sig 
193 SORBS2 E2sig 
194 SOX11 E2sig 
195 SPDEF E2sig 
196 STOX2 E2sig 
197 SYBU E2sig 
198 SYNJ2 E2sig 
199 SYT1 E2sig 
200 SYT7 E2sig 
201 TANK E2sig 
202 TAP2 E2sig 
203 TAPBP E2sig 
204 TBC1D9 E2sig 
205 TFF1 E2sig 
206 TGFA E2sig 
207 TGIF2 E2sig 
208 THBS1 E2sig 
209 TIPARP E2sig 
210 TJP3 E2sig 
211 TLE3 E2sig 
212 TM4SF1 E2sig 
213 TMPRSS2 E2sig 
214 TP53 E2sig 
215 TPBG E2sig 
216 TPD52L1 E2sig 
217 TRAF5 E2sig 
218 TRAP1 E2sig 
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219 TRPS1 E2sig 
220 TSC22D1 E2sig 
221 TSKU E2sig 
222 TSPAN5 E2sig 
223 TUBB2A E2sig 
224 TXNIP E2sig 
225 UBE2H E2sig 
226 UHRF1 E2sig 
227 USP25 E2sig 
228 USP53 E2sig 
229 VIM E2sig 
230 WT1 E2sig 
231 YPEL2 E2sig 
232 YRDC E2sig 
233 ZBTB38 E2sig 
234 ZFP36L2 E2sig 
235 ZMIZ1 E2sig 
236 ZWILCH E2sig 
237 ABL Endocrine rx 
238 AGR2 Endocrine rx 
239 AKT1 Endocrine rx 
240 AKT3 Endocrine rx 
241 AP-1 Endocrine rx 
242 ARHGDIA Endocrine rx 
243 BCAR1 Endocrine rx 
244 BCL2 Endocrine rx 
245 BIK Endocrine rx 
246 ERBB2 Endocrine rx 
247 ERBB3 Endocrine rx 
248 ESRRG Endocrine rx 
249 FGF17 Endocrine rx 
250 FGFR1 Endocrine rx 
251 FGFR2 Endocrine rx 
252 FGFR4 Endocrine rx 
253 HOXB13 Endocrine rx 
254 IGF1R Endocrine rx 
255 IL17BR Endocrine rx 
256 IL6 Endocrine rx 
257 JNK (MAPK8) Endocrine rx 
258 JUN Endocrine rx 
259 KGF Endocrine rx 
260 KRAS Endocrine rx 
261 MAPK Endocrine rx 
262 MET Endocrine rx 
263 NFKB Endocrine rx 
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264 NOTCH1 Endocrine rx 
265 NOTCH4 Endocrine rx 
266 PAX2 Endocrine rx 
267 PDGFRA Endocrine rx 
268 PDGFRB Endocrine rx 
269 PELP1 Endocrine rx 
270 PIK3CA Endocrine rx 
271 PTEN Endocrine rx 
272 SF3B3 Endocrine rx 
273 SNCG Endocrine rx 
274 SRC Endocrine rx 
275 STAT1 Endocrine rx 
276 STAT3 Endocrine rx 
277 STC2 Endocrine rx 
278 TGFBR2 Endocrine rx 
279 USP9X Endocrine rx 
280 WNT4 Endocrine rx 
281 ABCF1 HKG 
282 OAZ1 HKG 
283 RPLP0 HKG 
284 SDHA HKG 
285 ARG1 Immune 
286 BCL2L1 Immune 
287 CCL2 Immune 
288 CCL22 Immune 
289 CCL5 Immune 
290 CCR2 Immune 
291 CCR4 Immune 
292 CCR7 Immune 
293 CD3 Immune 
294 CD4 Immune 
295 CD8 Immune 
296 CTLA4 Immune 
297 CXCL10 Immune 
298 CXCL11 Immune 
299 CXCL12 Immune 
300 CXCL9 Immune 
301 CXCR3 Immune 
302 CXCR4 Immune 
303 EOMES Immune 
304 FASL Immune 
305 FOXM1 Immune 
306 FOXO1 Immune 
307 FOXP3 Immune 
308 GZMA Immune 
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309 GZMB Immune 
310 IDO Immune 
311 IFNG Immune 
312 IL10 Immune 
313 IL10RA Immune 
314 IL8 Immune 
315 IRF1 Immune 
316 LAG-3 Immune 
317 NOS2 Immune 
318 PD-1 Immune 
319 PD-L1 Immune 
320 Prf1 Immune 
321 PTGS2 Immune 
322 RORc Immune 
323 T-bet Immune 
324 Tcf1 Immune 
325 TGFB1 Immune 
326 TIM-3 Immune 
327 TNF Immune 
328 BIRC5/survivin Tumor / stroma interaction (McLean GOI) 
329 BMP2 Tumor / stroma interaction (McLean GOI) 
330 BMP4 Tumor / stroma interaction (McLean GOI) 
331 BMP6 Tumor / stroma interaction (McLean GOI) 
332 CCND1 Tumor / stroma interaction (McLean GOI) 
333 CCNE2 Tumor / stroma interaction (McLean GOI) 
334 CDH1 Tumor / stroma interaction (McLean GOI) 
335 CEBPB Tumor / stroma interaction (McLean GOI) 
336 COL1A1 Tumor / stroma interaction (McLean GOI) 
337 DDIT3 Tumor / stroma interaction (McLean GOI) 
338 GADD45A Tumor / stroma interaction (McLean GOI) 
339 GP130 Tumor / stroma interaction (McLean GOI) 
340 IHH Tumor / stroma interaction (McLean GOI) 
341 IL6R Tumor / stroma interaction (McLean GOI) 
342 LIF Tumor / stroma interaction (McLean GOI) 
343 MMP2 Tumor / stroma interaction (McLean GOI) 
344 MMP7 Tumor / stroma interaction (McLean GOI) 
345 MMP9 Tumor / stroma interaction (McLean GOI) 
346 PAPP-A Tumor / stroma interaction (McLean GOI) 
347 SHH Tumor / stroma interaction (McLean GOI) 
348 SPARC Tumor / stroma interaction (McLean GOI) 




The 207 genes identified by meta-analysis (Fig. 9) were validated in silico by supervised 
clustering of data from METABRIC and van’t Veer et al (performed by Soumya Luthra)240.  
E2sig expression was sufficient to separate ER+ from ER- breast tumors (A).  We also measured 
expression of the entire E2sig in PEO4 and MCF7 cells to confirm E2-regulation (B).  Cells were 
hormone-deprived as described in Chapter 2 and treated with vehicle or 1 nM E2 (3 hours for 
PEO4, 24 hours for MCF7).  Heat maps depict fold change vs. vehicle control. 
 
Figure 28: Validation of the E2sig.  A. Expression of 207 genes separates ER+ from ER- breast
tumors in two independent studies.  Analysis performed by S. Luthra.  B. Changes in expression
of the E2sig after estrogen treatment in PEO4 and MCF-7 cells.   Heat maps depict fold change
vs. vhc control. 
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APPENDIX C 
E2-REGULATED GENES IN PEO1 AND PEO4 CELLS IDENTIFIED BY 
MICROARRAY 
This appendix contains lists of genes significantly E2-regulated in PEO1 and PEO4 cells 
identified by microarray studies (described in Chapter 2).  Genes are listed in the order 
corresponding to the heat maps in Fig. 3, Chapter 2.  The tables show log2FC vs. vehicle control. 
 
Table 12: Ordered gene lists from PEO1 microarray heat maps in Fig. 3 
Symbol E2 4OHT+E2 4OHT ICI+E2 ICI 
ZNF37BP 0.368 -0.009 -0.055 0.083 0.075 
AP3M2 0.216 -0.111 -0.152 -0.022 -0.030 
OVOL2 0.305 -0.380 -0.458 -0.163 -0.193 
GAL 0.273 -0.009 -0.057 0.069 0.041 
OBTB1 0.436 -0.253 -0.369 0.005 -0.118 
SLC29A3 0.414 -0.301 -0.386 -0.146 -0.204 
SATB2 0.354 -0.240 -0.246 -0.121 -0.166 
RHOBTB3 0.570 -0.011 -0.030 0.106 0.051 
PLCL2 0.393 -0.129 -0.130 -0.029 -0.077 
OLFML3 0.643 -0.296 -0.349 -0.102 -0.230 
INHBB 0.457 -0.291 -0.345 -0.147 -0.218 
SDPR 0.281 -0.284 -0.273 -0.152 -0.083 
IRX5 0.394 -0.269 -0.270 -0.147 -0.108 
SLC22A4 0.454 -0.148 -0.122 0.069 -0.067 
INPP4B 0.279 -0.028 -0.001 0.079 0.042 
PTHLH 0.281 0.030 0.020 0.113 0.084 
MECOM 0.494 -0.118 -0.145 0.078 -0.022 
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HERC1 0.279 -0.088 -0.078 0.056 -0.010 
RHOBTB3 0.561 -0.275 -0.170 0.148 -0.078 
POLR1E 0.243 -0.075 -0.081 0.068 -0.021 
AMPD3 0.213 -0.026 -0.041 0.062 -0.027 
TNPO2 0.299 0.091 0.017 0.059 0.077 
SMYD2 0.418 0.079 -0.009 0.065 0.046 
PDLIM4 0.245 0.034 -0.029 0.017 0.001 
PDZK1 0.480 -0.052 -0.135 -0.095 -0.084 
OTUB2 0.352 -0.083 -0.185 -0.137 -0.149 
PPP1R1A 0.345 -0.031 -0.209 -0.082 -0.132 
CACNA1I 0.365 0.059 -0.159 -0.028 -0.069 
GLI3 0.262 0.001 -0.127 -0.006 -0.018 
CUEDC1 0.331 0.094 -0.035 0.068 0.049 
MAFB 0.251 0.034 -0.119 -0.035 -0.002 
RAB17 0.177 -0.062 -0.172 -0.050 -0.035 
PORCN 0.245 0.069 -0.055 0.063 0.062 
RIN3 0.177 0.075 0.012 0.094 0.030 
ASB13 0.270 -0.019 -0.146 0.037 -0.113 
IVL 0.437 0.205 0.087 0.273 0.153 
FJX1 0.225 0.035 -0.048 0.095 -0.020 
CYR61 0.266 0.030 -0.043 0.081 -0.010 
POLR1C 0.200 0.023 -0.030 0.050 0.010 
BNC2 0.447 -0.130 -0.333 -0.067 -0.139 
ITPK1 0.249 0.013 -0.095 0.042 -0.019 
NCOR2 0.221 0.028 -0.032 0.077 0.033 
ZNF195 0.253 0.037 0.069 0.080 0.082 
TSPAN5 0.320 -0.056 -0.034 0.027 0.000 
DEPTOR 0.808 -0.333 -0.312 -0.124 -0.159 
BCL11A 0.315 -0.242 -0.201 -0.143 -0.143 
ZMIZ1 0.606 -0.043 -0.056 0.001 -0.009 
MPPED2 0.510 -0.204 -0.196 -0.150 -0.122 
THY1 0.251 0.004 0.012 0.009 0.027 
NPY1R 0.654 -0.207 -0.224 -0.212 -0.174 
NRTN 0.557 -0.237 -0.157 -0.128 -0.227 
ELF3 0.261 -0.180 -0.144 -0.155 -0.164 
FLG 0.434 -0.550 -0.388 -0.212 -0.368 
MICAL3 0.224 -0.080 -0.039 0.034 -0.042 
HIP1 0.445 -0.097 -0.014 0.040 -0.043 
TMEM120B 0.623 -0.002 -0.096 0.003 -0.113 
SLC7A2 0.813 -0.167 -0.322 -0.160 -0.340 
RBBP8 0.493 -0.277 -0.374 -0.267 -0.376 
MPHOSPH10 0.229 0.003 -0.003 0.034 -0.003 
GREB1 1.960 -0.686 -0.842 -0.334 -0.777 
CADM1 1.002 0.044 -0.035 0.115 -0.031 
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SLC9A3R1 0.242 -0.030 -0.070 -0.015 -0.045 
SLC22A5 0.673 -0.162 -0.286 -0.102 -0.200 
PAPSS2 0.761 0.074 -0.030 0.088 0.035 
HIPK2 0.271 0.044 -0.022 0.037 -0.013 
TGFA 0.290 -0.136 -0.152 -0.043 -0.158 
ARHGAP26 1.084 0.017 0.022 0.217 -0.068 
PLAT 0.765 -0.149 -0.269 -0.052 -0.340 
E2F6 0.250 -0.064 -0.120 -0.038 -0.133 
MDN1 0.301 0.018 -0.024 0.077 -0.022 
LOC100505650 0.447 0.025 -0.069 0.081 -0.036 
ABCC1 0.236 -0.012 -0.053 0.027 -0.037 
PDGFRL 0.586 -0.042 -0.060 0.010 -0.122 
CA12 1.128 0.031 -0.041 0.065 -0.123 
CA12 1.406 0.041 -0.047 0.110 -0.263 
ARNTL 0.777 0.026 0.029 0.111 -0.097 
NRP1 0.334 -0.092 -0.089 -0.005 -0.161 
ARHGAP26 0.871 0.176 0.155 0.296 -0.005 
LYN 0.378 0.017 -0.014 0.009 -0.101 
BCL2L11 0.416 -0.011 -0.027 0.013 -0.131 
ARL4C 0.221 0.004 -0.027 0.005 -0.071 
DGKI 0.435 0.116 0.071 0.143 -0.014 
CBLN1 0.572 -0.337 -0.476 -0.255 -0.620 
TGIF2 0.450 -0.160 0.031 -0.055 -0.168 
DDX24 0.226 0.046 0.087 0.081 0.051 
NOLC1 0.263 0.026 0.089 0.096 0.030 
ABAT 0.302 0.007 0.097 0.111 0.026 
RASGRP1 0.295 -0.124 -0.124 -0.115 -0.279 
BCL2L11 0.551 0.104 0.092 0.106 -0.091 
PRLR 0.422 0.184 0.200 0.215 0.095 
MED13L 0.378 -0.002 0.048 0.034 -0.070 
AGT 0.641 -0.083 -0.026 -0.062 -0.175 
OLFM1 0.818 -0.192 -0.137 -0.227 -0.276 
CA12 0.953 -0.071 -0.060 -0.109 -0.148 
KDM4B 0.370 -0.055 -0.035 -0.102 -0.108 
GFRA2 0.811 0.006 0.001 -0.077 -0.123 
FAM134B 0.303 0.133 0.132 0.112 0.096 
ZNF3 0.268 0.033 -0.034 0.065 -0.120 
C10orf2 0.243 0.055 -0.002 0.039 -0.099 
ULK1 0.297 0.149 0.034 0.118 0.027 
POP1 0.228 0.058 -0.090 0.010 -0.100 
PPRC1 0.217 0.089 -0.030 0.051 -0.055 
MUC4 0.319 0.110 -0.101 0.060 -0.055 
SYNJ2 0.272 0.113 0.026 0.099 0.026 
CHST10 0.341 -0.037 -0.215 -0.053 -0.202 
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SCNN1B 0.383 0.015 -0.124 -0.040 -0.159 
KAZN 0.697 -0.039 -0.214 -0.140 -0.357 
NT5DC3 0.265 0.043 -0.042 0.018 -0.089 
SLC7A6 0.230 0.009 -0.019 0.090 -0.105 
POLR3E 0.170 0.000 0.001 0.075 -0.023 
PDLIM4 0.358 0.037 0.031 0.149 0.000 
PLCL2 0.448 0.102 0.106 0.216 0.019 
AKAP1 0.277 -0.013 -0.083 0.124 -0.074 
TLE3 0.241 0.128 -0.038 0.130 0.061 
RDX 0.197 -0.363 -0.262 0.022 -0.064 
NEDD9 0.225 -0.016 -0.068 0.088 0.085 
GPR135 0.277 0.034 0.030 0.127 0.169 
PPP1R3D 0.422 -0.036 0.125 0.083 0.146 
NFAT5 0.400 0.015 0.088 0.076 0.212 
MYO10 0.358 -0.002 -0.004 -0.114 0.134 
EDAR 0.310 0.035 -0.136 -0.062 0.090 
VNN1 0.390 0.161 0.233 0.114 -0.032 
MAP3K9 0.258 0.082 0.144 0.061 -0.070 
INHBA 0.540 0.245 0.298 0.179 -0.090 
SLC25A36 0.207 0.103 0.083 0.063 -0.075 
PPAT 0.222 0.070 0.060 0.051 -0.088 
PNN 0.224 0.120 0.108 0.121 0.013 
PTHLH 0.369 0.202 0.235 0.177 0.116 
PTGS2 0.586 0.045 0.185 0.093 -0.162 
TGIF2 0.202 -0.036 -0.029 -0.052 -0.117 
ARNTL 0.676 0.158 0.148 0.068 -0.082 
KIAA1199 0.406 -0.031 -0.074 -0.076 -0.192 
CISH 0.621 -0.291 -0.375 -0.450 -0.607 
STC2 0.424 0.043 -0.009 -0.131 -0.254 
KCNF1 1.014 0.159 0.092 -0.118 -0.298 
IL12A 0.899 0.006 0.099 -0.156 -0.284 
SOX9 0.337 0.067 -0.010 -0.058 -0.147 
C16orf45 0.384 0.109 0.040 -0.017 -0.089 
PDLIM4 0.765 0.312 0.143 0.113 -0.084 
MREG 0.272 0.064 -0.024 -0.010 -0.087 
LYN 0.361 0.113 0.069 0.065 -0.049 
TFAP2C 0.304 -0.125 -0.219 -0.199 -0.242 
ST6GALNAC2 0.285 -0.066 -0.156 -0.122 -0.168 
PLCG2 0.407 0.020 -0.010 -0.050 -0.037 
DHRS2 0.329 0.055 -0.075 -0.043 -0.085 
BDNF 0.307 0.085 0.016 0.007 0.004 
SHB 0.351 0.166 0.029 0.001 -0.029 
MAP3K4 0.214 0.098 0.015 -0.002 -0.008 
IGF1R 0.424 0.158 -0.024 -0.016 -0.066 
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COBL 0.397 0.171 -0.015 -0.016 -0.075 
KIAA0485 0.803 0.295 -0.066 -0.149 -0.094 
PCNX 0.214 0.144 0.051 0.056 0.020 
SLC7A5 0.384 0.265 0.106 0.099 -0.025 
JARID2 0.624 0.463 0.311 0.323 0.085 
SHB 0.342 0.163 0.102 0.027 -0.053 
EDN1 0.302 0.144 0.086 0.012 -0.063 
RHOF 0.282 0.170 0.093 0.061 -0.005 
OSBPL3 0.770 0.442 0.247 0.175 0.053 
KIAA0226L 0.627 0.428 0.210 -0.038 -0.155 
BMP2 0.546 0.315 0.064 -0.190 -0.356 
BMP2 0.461 0.199 -0.001 -0.172 -0.346 
INHBA 0.429 0.288 0.166 -0.014 -0.153 
DIRAS3 0.300 0.180 0.099 -0.038 -0.185 
KIAA0226L 0.514 0.296 0.219 -0.009 -0.075 
TXLNG 0.302 0.173 0.227 0.008 0.028 
BCL10 0.244 0.110 0.120 -0.038 -0.020 
TIPARP 0.263 0.106 0.117 -0.014 -0.034 
MYC 0.235 -0.155 -0.141 -0.358 -0.477 
LPIN1 0.273 0.087 0.127 -0.092 -0.116 
KLF4 0.496 0.161 0.258 -0.169 -0.277 
KLF4 0.604 0.230 0.238 -0.174 -0.335 
SRRM2 0.270 0.118 0.107 -0.020 0.028 
SLC4A7 0.281 0.154 0.168 0.040 0.146 
SOWAHC 0.218 0.420 0.338 0.043 -0.119 
FOS 0.351 0.609 0.561 -0.321 -0.412 
EGR1 0.433 0.851 1.001 -0.144 -0.309 
DNMBP 0.262 0.440 0.261 0.070 -0.060 
ABTB2 0.256 0.306 0.209 0.116 0.035 
BIRC3 0.412 0.491 0.411 0.018 -0.169 
SF1 0.470 0.605 0.677 0.412 0.155 
EGR3 0.704 0.729 1.095 0.113 -0.029 
SLC19A2 0.647 0.544 0.390 -0.096 -0.305 
MAPKBP1 0.385 0.323 0.223 -0.014 -0.203 
PPAP2B 0.418 0.356 0.325 0.047 -0.108 
LPIN1 0.263 0.152 0.175 -0.046 -0.148 
EXT1 0.396 0.305 0.397 0.204 0.116 
PPAP2B 0.405 0.400 0.207 -0.026 -0.079 
CENPJ 0.369 0.136 0.413 0.290 0.241 
ZIC1 -0.238 -0.203 -0.195 -0.098 -0.060 
SMAD6 -0.286 -0.231 -0.253 -0.083 0.004 
FZD7 -0.405 -0.245 -0.256 0.126 0.145 
GAS1 -0.468 -0.464 -0.360 0.064 0.142 
C1orf106 -0.220 -0.200 -0.229 0.096 0.087 
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ADM -0.217 -0.193 -0.204 0.076 0.083 
BMP4 -0.278 -0.235 -0.280 0.088 0.130 
FLVCR2 -0.250 -0.297 -0.274 -0.068 -0.012 
NR3C2 -0.273 -0.346 -0.413 -0.103 -0.050 
PRR15L -0.251 -0.608 -0.553 -0.146 -0.130 
CCNG2 -0.296 -0.566 -0.354 -0.188 -0.126 
CYP1B1 -0.268 -0.388 -0.179 -0.090 -0.117 
ZBED2 -0.323 -0.054 -0.121 0.167 0.134 
JAG1 -0.276 0.007 -0.069 0.173 0.228 
TOX -0.460 -0.244 -0.222 -0.043 0.067 
FAM49A -0.323 -0.084 -0.154 -0.043 0.006 
TLE4 -0.418 -0.275 -0.080 -0.138 -0.141 
LYST -0.394 -0.248 -0.032 -0.112 -0.129 
DDX25 -0.348 -0.245 -0.118 -0.118 -0.160 
PLAU -0.367 -0.085 0.055 0.117 0.085 
NAP1L3 -0.241 -0.097 -0.048 0.062 -0.008 
THEMIS2 -0.234 -0.188 -0.165 -0.068 -0.078 
STYK1 -0.221 -0.089 -0.084 0.120 0.057 
THEMIS2 -0.283 -0.266 -0.166 -0.086 -0.144 
CLEC7A -0.236 -0.210 -0.121 -0.116 -0.098 
CCNG2 -0.387 -0.391 -0.163 -0.090 0.049 
SLC39A2 -0.332 -0.095 -0.317 -0.175 -0.113 
PDGFA -0.269 0.055 -0.031 0.053 0.084 
DIO2 -0.465 0.228 0.058 0.123 0.259 
EPHB3 -0.299 0.023 -0.117 -0.020 0.022 
GTF2IRD1 -0.202 0.005 -0.073 0.020 -0.003 
LEF1 -0.429 0.056 -0.159 -0.058 -0.062 
ADCY2 -0.294 -0.051 -0.147 -0.180 -0.101 
TSC22D1 -0.299 0.090 0.136 0.067 0.083 
ARID5B -0.451 0.172 0.305 0.081 0.149 
KLF9 -0.521 -0.008 0.286 0.075 0.097 
FRMD4B -0.357 0.077 0.224 0.159 0.144 
TBX2 -0.260 -0.126 -0.072 -0.118 -0.146 
BCAR3 -0.306 0.105 0.132 0.086 0.014 
TNFRSF11B -0.385 -0.061 0.000 -0.007 0.084 
TNFAIP8 -0.339 0.049 0.089 0.107 0.155 
TNFAIP8 -0.353 0.046 0.125 0.083 0.139 
PLAU -0.311 0.055 0.067 0.138 0.104 
DLX2 -0.424 0.021 0.016 0.139 0.116 
EPHB3 -0.379 -0.099 -0.108 -0.076 -0.064 
EFNB2 -0.281 0.084 0.028 0.080 0.109 
KIR3DL3 -0.308 -0.091 -0.067 -0.095 0.036 
ACTG2 -0.240 -0.134 -0.088 -0.158 -0.089 
TRIM24 -0.225 0.034 0.045 -0.087 -0.087 
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SPAG11B -0.423 -0.167 -0.195 -0.281 -0.271 
SAMD4A -0.201 0.389 0.309 0.087 0.077 
CYP26B1 -0.320 0.208 0.294 0.050 0.048 
ACRV1 -0.243 0.032 0.085 -0.070 -0.076 
CITED2 -0.268 0.224 0.261 0.107 0.060 
NPTXR -0.217 0.043 0.046 -0.109 -0.015 
TP63 -0.312 0.001 -0.022 -0.269 -0.173 
KCNJ3 -0.188 -0.075 -0.014 -0.048 -0.160 
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Table 13: Ordered gene lists from PEO4 heat maps in Fig. 3 
Genes E2 4OHT+E2 4OHT ICI+E2 ICI 
ZNF667 0.3552 -0.0769 0.0239 0.0939 0.0872 
TSPAN15 0.6606 -0.0764 0.0698 0.1413 0.1682 
RAB7L1 0.3069 -0.4052 -0.2600 -0.1958 -0.2313 
PPP1R3D 0.2689 -0.0253 0.0037 0.0668 0.0216 
MINA 0.3361 -0.1320 -0.0416 0.0362 -0.0714 
PELI1 0.3748 -0.0763 0.0809 0.0580 0.0362 
MYBL1 0.5997 0.1592 0.3407 0.2858 0.2496 
BRIX1 0.2972 0.1473 0.1590 0.1555 0.1230 
SLC7A2 0.4789 -0.0050 0.0233 0.0357 -0.1466 
PPAT 0.3505 0.0451 0.0738 0.1010 -0.0208 
FASTKD3 0.3043 0.0869 0.0796 0.1252 0.0582 
SCNN1B 0.2544 0.1565 0.1619 0.1865 0.1431 
QTRTD1 0.2739 0.0542 0.0337 0.1291 -0.0108 
ID4 0.2325 0.0624 0.1078 0.1214 0.0556 
WDR3 0.4131 0.1307 0.1693 0.1131 0.1540 
TGIF2 0.5028 0.1411 0.1051 0.0679 0.1248 
PRR5 0.3249 0.0054 -0.0272 -0.0359 0.0057 
CACNA1I 0.9547 0.2536 0.2673 0.1253 0.3268 
LIMS1 0.2485 0.1487 0.1641 0.1247 0.1436 
RBBP8 0.6175 0.1939 0.2657 0.1518 0.1038 
IL15 0.3273 0.0758 0.1492 0.1018 0.0540 
TLL2 0.6063 0.0587 -0.1283 -0.0607 -0.2265 
SOX17 0.3029 0.0429 -0.0318 -0.0468 -0.0923 
ITSN2 0.2968 0.0800 0.0107 0.0077 -0.0305 
KAZN 0.5299 0.1064 -0.0214 -0.0160 -0.0547 
AKAP1 0.3471 0.1268 0.0183 0.0620 -0.0163 
TIMM8A 0.1970 0.1048 0.0769 0.0557 0.0479 
IL12A 1.0210 0.3535 0.1338 -0.0121 -0.1101 
RASGRP1 1.9351 1.0155 0.9086 0.5433 0.5247 
SHB 0.4212 0.2594 0.1746 0.1139 0.1159 
PVR 0.3297 0.2089 0.1313 0.1026 0.0691 
PEX5 0.2623 0.1653 0.1035 0.0788 0.0653 
OSBPL3 0.7383 0.3069 -0.0119 -0.0026 -0.0039 
STC2 0.4590 0.1860 0.0683 -0.0225 0.0697 
E2F6 0.2543 0.1019 0.0506 -0.0140 0.0631 
SLC7A5 0.3071 0.1820 0.1438 0.0600 0.1402 
DHODH 0.2863 0.1705 0.1449 0.0744 0.1327 
SPRY1 0.3181 0.0284 -0.0330 -0.2160 -0.1745 
PLEKHF1 0.3339 0.1489 0.1395 0.0097 0.0373 
SIX1 0.8042 0.4576 0.4064 0.1737 0.2887 
HES1 0.5398 0.3155 0.2516 0.0911 0.1657 
PPRC1 0.3750 0.2022 0.1574 0.0670 0.1111 
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CD3EAP 0.4827 0.2655 0.1994 0.1058 0.1645 
ARL4C 0.4085 0.2329 0.1656 0.0796 0.1150 
TSEN2 0.4651 0.0025 -0.0069 -0.0124 -0.0914 
PLCL2 0.6375 0.0323 0.0191 0.0199 -0.0630 
CEBPD 0.8994 0.1435 0.0952 -0.0053 -0.0371 
PLAT 0.5546 0.1539 0.1660 0.1363 0.1505 
KAZN 1.3479 0.4207 0.3601 0.2578 0.3092 
HES1 0.5794 0.1329 0.0952 0.0276 0.0627 
SLC22A5 0.6618 0.1217 -0.0270 0.0739 0.0685 
PPYR1 0.2796 -0.0956 -0.1485 -0.0993 -0.1311 
PLCL2 0.9662 0.0780 -0.0823 -0.0547 -0.1294 
CA12 1.2262 0.2389 0.0827 0.1097 0.0940 
ERG 0.6679 0.0642 -0.0003 0.0386 -0.0142 
SYBU 0.3378 0.1655 0.1279 0.1250 0.1371 
LOC100505650 0.8342 0.2002 -0.0475 0.0032 0.1073 
FLG 0.5949 0.0154 -0.2486 -0.1448 -0.0576 
FAM134B 0.2746 0.0077 -0.1036 -0.0536 -0.0127 
TMPRSS3 0.5034 -0.0418 -0.1119 0.0036 0.0974 
RPS6KA2 0.5808 -0.0847 -0.2036 -0.0452 0.0873 
PIPOX 0.5089 -0.0588 -0.1474 -0.0882 0.0856 
MLPH 0.3057 -0.0696 -0.1226 -0.0924 0.0334 
BICD1 0.2861 0.0510 -0.0353 0.0413 0.0787 
DEPTOR 1.1935 -0.1305 -0.1044 0.0664 0.0693 
GREB1 1.6996 -0.1307 -0.0878 0.2120 0.0213 
OLFML3 1.1165 -0.0534 -0.0886 -0.0534 0.1094 
GFRA2 1.0756 0.1754 0.1944 0.2129 0.2462 
PKNOX2 1.2580 0.1582 -0.0136 0.2707 0.3763 
F13A1 0.2870 -0.2149 -0.2665 -0.1577 -0.1261 
CASQ2 0.5071 -0.4493 -0.5533 -0.2754 -0.2099 
BMP7 0.5901 -0.1642 -0.2030 -0.0862 -0.0396 
TPST2 0.3431 0.0092 0.0462 0.0142 0.1293 
ST6GALNAC2 0.4364 0.0252 0.0106 -0.0471 0.1183 
RAB17 0.3076 0.0439 0.0488 0.0165 0.1146 
CRYBG3 0.3883 0.0763 0.0593 0.0479 0.1637 
SRSF7 0.3267 0.1260 0.1146 0.0740 0.1637 
TBC1D16 0.4292 0.0489 -0.0406 -0.0420 0.1028 
ABCC1 0.3037 0.1020 0.0518 0.0394 0.1141 
PRR5 0.3717 0.0705 -0.0348 -0.0415 0.1319 
RCL1 0.2766 0.1001 -0.0033 -0.0292 0.0908 
RAP1GAP 0.4130 0.1158 -0.0125 -0.0645 0.1257 
MPPED2 0.5915 -0.1346 -0.3624 -0.1615 -0.1355 
LRRC8B 0.3537 -0.1291 -0.2264 -0.1207 -0.1072 
PDGFRL 0.3488 -0.0346 -0.1136 0.0116 -0.0146 
FRAT2 0.3173 0.0094 -0.1090 0.0259 -0.0049 
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FAM216A 0.3942 0.1249 0.0355 0.1101 0.0815 
METTL21B 0.3171 0.1888 0.0991 0.1785 0.1311 
ZMIZ1 0.3207 0.0047 0.0077 0.0691 0.1277 
TNS1 0.2711 0.0091 0.0028 0.0512 0.1275 
CHD7 0.3071 0.2028 0.2090 0.2281 0.2520 
ELF3 0.4255 -0.1842 -0.3398 -0.1218 0.0678 
VAX2 0.3339 -0.0904 -0.0817 -0.0152 0.1763 
PDZK1 0.2566 -0.2844 -0.3013 -0.0767 0.0081 
OVOL2 0.3165 -0.3349 -0.2974 -0.0897 0.0627 
UGT2B28 0.4130 -0.0961 -0.1136 0.0490 0.0621 
RHOBTB1 0.3337 -0.1699 -0.1966 -0.0262 -0.0375 
BCL11A 0.6948 -0.0553 -0.0681 0.2210 0.1584 
ABCC4 0.2140 0.0151 -0.0173 0.0715 0.0762 
CEP68 0.2557 -0.1435 -0.1253 0.0490 0.0190 
TMEM177 0.2114 -0.0231 0.0378 0.0700 0.1354 
BNC2 0.2388 -0.3551 -0.2982 -0.0887 0.1240 
DAAM1 0.3327 -0.5012 -0.3517 0.0669 0.0267 
ZNF573 0.2746 0.0221 -0.2128 -0.0115 0.0998 
TMEM47 0.2393 0.0659 -0.1257 0.0304 0.0898 
SCAMP1 0.3004 0.1180 -0.1122 0.0416 0.1679 
SV2A 0.2987 0.0027 -0.1641 -0.0605 0.0997 
THY1 0.2685 0.0694 -0.0049 0.0336 0.2240 
GEMIN4 0.2041 0.1222 0.0471 0.0300 0.2016 
ZNF556 0.3332 0.2406 0.1861 -0.0051 0.1133 
HK2 0.2740 0.1959 0.1377 -0.0144 0.1199 
RGS16 0.5206 0.2805 0.3274 -0.0106 0.1475 
ZNF232 0.2998 0.2536 0.1356 0.1301 0.1673 
DIEXF 0.2971 0.2341 0.0288 0.0329 0.1101 
JARID2 0.3921 0.3349 0.0168 -0.0049 0.1012 
TSKU 0.3498 0.2734 0.1621 0.1101 0.1653 
SCARB1 0.2308 0.1646 0.0220 -0.0242 0.0389 
LRP8 0.2228 0.1864 0.1260 0.1036 0.1417 
C10orf2 0.4579 0.2894 0.0982 -0.0442 0.0544 
MID1IP1 0.2905 0.1633 0.0265 -0.0411 0.0064 
NXT1 0.3052 0.2237 0.0642 -0.0284 0.0143 
CHST10 0.3109 0.2166 0.0775 0.0297 0.0474 
SIN3B 0.3394 0.1275 -0.1047 -0.1671 0.0091 
DPH2 0.2407 0.1554 0.0615 0.0418 0.0991 
TBC1D30 0.4505 0.2055 -0.1598 0.0117 0.1203 
DFFB 0.3175 0.1613 0.0008 0.0608 0.1258 
KIAA1199 0.6737 0.2529 -0.0752 0.0044 0.1071 
CADM1 0.3000 0.1189 -0.0336 0.0073 0.0658 
GPD1L 0.2100 0.0794 -0.0100 -0.0008 0.0631 
TACSTD2 0.2859 0.1674 -0.0136 0.0014 0.1297 
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RARA 0.3176 0.2933 0.1677 0.1139 0.2887 
PADI2 0.2979 0.2351 0.1027 0.0042 0.1667 
YRDC 0.2179 0.3158 0.1879 0.0397 -0.0036 
SLC19A2 0.4193 0.5938 0.4120 0.1962 0.1337 
PDLIM4 0.4747 0.7631 0.4008 0.0824 -0.0175 
PWP2 0.2646 0.3380 0.2416 0.0870 0.1103 
TNFRSF10B 0.3603 0.6171 0.4044 0.1914 0.2615 
COBL 0.4617 0.8233 0.5007 0.1419 0.2595 
PPP1R3C 0.3386 0.7255 0.5530 0.1055 0.1291 
KLHL21 0.4647 0.8082 0.6152 0.2871 0.2999 
BIRC3 0.4027 1.0582 0.5856 -0.1035 -0.1818 
PPAP2B 0.4248 0.7900 0.3171 0.1073 0.1157 
INHBB 0.3628 0.5238 0.2232 0.0797 0.0838 
MAP3K9 0.3263 0.4835 0.2487 0.0982 0.2064 
CAMK2N1 0.2811 0.4417 0.1588 0.0715 0.1287 
TTC9 0.3559 0.3957 0.2335 0.0793 0.1266 
LHX6 0.3752 0.3501    0.2496 0.1248 0.1846 
KIAA0226L 0.8586 0.8441 0.4525 0.0703 0.1300 
GRPEL1 0.3289 0.2921 0.1680 0.0179 0.0275 
ABTB2 0.5835 0.5265 0.3328 0.1369 0.1600 
THBD 0.8094 0.9029 0.6056 0.1538 -0.0443 
MAK16 0.2499 0.2714 0.1939 0.0785 0.0557 
POP1 0.2618 0.2669 0.1749 0.0507 0.0211 
MREG 0.3732 0.3570 0.2655 0.1051 0.0642 
BMP2 0.5114 0.6059 0.3898 0.1637 0.0837 
IL24 0.5889 0.6590 0.4094 0.1947 0.1315 
INHBA 0.5411 0.5265 0.3686 0.0511 0.1084 
DUSP2 0.7166 0.7038 0.5417 0.0762 0.0956 
SOWAHC 0.5345 0.5749 0.4996 0.1875 0.1198 
BDNF 0.5648 0.5257 0.4929 0.1527 0.0380 
ANKRD1 0.3665 0.3089 0.2091 -0.0184 -0.1366 
MNT 0.4094 0.5527 0.3960 0.1006 0.2792 
CAMSAP1 0.3008 0.4309 0.3132 0.0570 0.1515 
BDKRB1 0.5414 0.6045 0.4470 0.0981 0.2966 
CCDC86 0.2779 0.2822 0.2250 0.0956 0.2120 
MAPKBP1 0.4186 0.4033 0.1469 -0.0026 0.2110 
IVL 0.6133 0.6456 0.4284 0.2898 0.4722 
IFIT5 0.2377 0.2560 0.1472 0.0455 0.1607 
FZD5 0.2526 0.2549 0.0777 0.0018 0.0772 
ZNF239 0.4436 0.2621 0.1688 0.0530 0.0083 
KLF4 0.9665 0.5092 0.4584 0.1251 0.0701 
MYC 0.9676 0.5374 0.5306 0.0334 -0.1512 
FJX1 0.4792 0.3343 0.3141 0.1564 0.1020 
TMEM30B 0.3415 0.2058 0.1963 0.1284 0.0567 
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TGFA 0.3010 0.1511 0.1447 0.0994 -0.0443 
RRS1 0.3913 0.1886 0.1402 0.1045 0.0042 
DIEXF 0.4865 0.3124 0.2630 0.2348 0.1163 
PNPLA3 0.5198 0.2601 0.1367 0.1039 -0.0407 
GEMIN6 0.2397 0.0853 -0.0018 0.0022 -0.0859 
EIF3M 0.4329 0.2451 0.1185 0.1365 0.0233 
PPAT 0.3354 0.1533 0.1310 0.1062 0.0419 
POLR1E 0.3730 0.1131 0.1176 0.0251 -0.0621 
UCK2 0.2842 0.2278 0.1856 0.1058 0.0771 
OTUB2 1.0120 0.7949 0.6089 0.2223 0.1990 
NOP16 0.4321 0.3823 0.2616 0.1048 0.0667 
POLR1C 0.4048 0.2884 0.1316 0.0233 -0.0724 
HRH1 0.5150 0.3716 0.2263 0.1401 0.0424 
B4GALT5 0.2813 0.2127 0.1417 0.0882 0.0700 
SOX9 0.7748 0.7645 0.4565 0.2696 0.1883 
PER2 0.3056 0.2766 0.1349 0.0351 -0.0466 
TFAP2C 0.5288 0.3942 0.3178 0.1146 -0.2247 
SLC30A1 0.2856 0.2406 0.2079 0.1642 0.1241 
POLR3K 0.2145 0.1654 0.1147 0.0564 -0.0076 
EHD1 0.3014 0.2181 0.1275 0.0489 -0.0687 
NOP16 0.5264 0.3508 0.2873 0.2127 0.0644 
ZFP36L2 0.2924 0.0985 0.2229 0.0467 -0.0698 
TFB2M 0.2816 0.1024 0.1619 0.0711 -0.0409 
E2F5 0.2358 -0.0351 0.0601 -0.0107 -0.3772 
NIP7 0.3737 0.0568 0.1275 0.1301 -0.1374 
MRPS30 0.1906 0.1170 0.0678 0.0609 -0.1084 
LOC389906 0.3647 0.2441 0.1628 0.2260 0.0330 
TBC1D9 0.2289 0.2070 0.0911 0.1270 0.0428 
MN1 0.3772 0.3695 0.0372 0.0461 0.0124 
POLR3G 0.3727 0.2493 0.0728 0.1118 0.0742 
EDAR 0.4871 0.3048 0.1147 0.1741 0.1363 
LYN 0.2458 0.1744 0.0255 0.1155 0.0444 
FUT9 -0.2264 -0.2631 -0.3893 -0.3317 -0.3616 
F3 0.4550 0.6453 0.6433 0.2152 0.0686 
BAZ1A 0.2774 0.3484 0.3347 0.2292 0.1640 
DUSP7 0.3288 0.4459 0.3832 0.1711 0.1081 
RALA 0.2565 0.3936 0.3047 0.2430 0.0884 
NDUFAF4 0.2256 0.2229 0.1872 0.1288 -0.0424 
ZFP161 -0.2159 -0.2730 0.2485 0.1245 -0.4254 
SCN2B -0.3887 -0.3218 -0.3003 -0.2328 -0.4112 
ITGB4 -0.2414 -0.1528 -0.2007 -0.0738 -0.3418 
DNAJB4 -0.5180 -0.7041 -0.3485 -0.3306 -0.7904 
C19orf6 -0.3883 -0.3998 -0.2319 -0.1975 -0.4863 
TOB1 -0.2287 -0.0645 0.0240 -0.0085 -0.1282 
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PALLD -0.2790 -0.0806 0.0343 0.0242 -0.2047 
PAX8 -0.3546 -0.1074 0.0937 -0.0477 -0.2607 
KLF9 -0.4191 0.0483 0.1937 0.0955 -0.2370 
ARF6 -0.3195 -0.2144 -0.0351 -0.1164 -0.2834 
RNFT1 -0.6682 -0.4867 -0.2238 -0.2865 -0.8099 
PLAU -0.4054 -0.1025 0.1237 -0.0613 -0.5188 
PHACTR2 -0.2546 -0.1611 0.0276 0.0515 -0.0769 
HOXB3 -0.2478 -0.1946 0.0408 0.0813 -0.1635 
MLL -0.3227 -0.2800 -0.1122 0.0709 -0.1494 
CTGF -0.4861 -0.5214 -0.3154 -0.2734  -0.3653 
COL1A1 -0.2693 -0.2792 -0.2647 -0.0060 -0.1642 
HEXIM1 -0.2504 -0.3087 -0.2501 -0.0813 -0.2215 
LIMK2 -0.4008 -0.4585 -0.4218 -0.1905 -0.4401 
IQGAP2 -0.3219 -0.3278 -0.3437 -0.2869 -0.3140 
TSPAN2 -0.3278 -0.5207 -0.5113 -0.3514 -0.5287 
TM4SF1 -0.4088 -0.0937 -0.0478 -0.3017 -0.4725 
SERPINB2 -0.2885 0.0352 0.0285 -0.1997 -0.2880 
DUSP1 -0.6017 -0.2579 -0.0765 -0.3844 -0.6249 
CITED2 -0.3602 0.1175 0.2220 -0.0676 -0.3661 
SLIT2 -0.2432 0.4313 0.1369 -0.0704 -0.0590 
HNRNPU -0.3214 -0.0573 -0.1859 -0.2262 -0.2057 
CADM4 -0.3277 -0.1793 -0.2800 -0.2940 -0.2809 
DKK1 -0.5820 0.9109 0.5376 0.3115 0.1549 
ARID5B -0.5860 0.1775 -0.0188 -0.2214 -0.1316 
PCDH7 -0.2766 0.8566 0.6994 0.2109 0.2177 
DUSP5 -0.3530 0.5775 0.4755 -0.0941 -0.1925 
AREG -0.4199 1.3772 1.0216 0.0958 -0.1860 
SLC35G2 0.2236 0.6209 0.5146 0.2118 0.0865 
DNMBP 0.2612 0.8908 0.6513 0.1501 0.1138 
RSRC2 -0.2677 -0.0662 -0.1470 -0.0582 -0.2324 
PPFIBP1 -0.4894 0.0399 -0.0840 0.1401 -0.2665 
FZD7 -0.3318 -0.0203 -0.1931 -0.0545 -0.2449 
RNF19A -0.4274 0.0373 -0.0736 0.0806 -0.0568 
PDP1 -0.4896 0.1347 0.1642 0.0230 -0.1575 
EZR -0.2830 0.2752 0.3306 0.2698 0.0744 
EFNB2 -0.4112 0.4213 0.3172 0.2116 0.2719 
FAM49A -0.3242 -0.0138 -0.0531 -0.0482 -0.0751 
KLF5 -0.4900 0.1356 0.0365 -0.0290 -0.1201 
PTGER4 -0.2839 0.0607 -0.1772 -0.1320 -0.1168 
CXCR4 -0.3084 0.0747 -0.1973 -0.1487 -0.0420 
ZBED2 -0.3550 -0.1004 -0.0832 -0.1162 -0.0401 
EPHB3 -0.3777 0.0134 0.0811 0.0022 0.1166 
NRG1 -0.3674 -0.0370 -0.0161 -0.1202 -0.0485 
ADM -0.2855 0.0167 0.0252 -0.0096 0.1867 
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TSC22D1 -0.2559 -0.1319 -0.1619 -0.0434 -0.0473 
PCDH9 -0.4644 -0.2752 -0.3280 -0.0589 0.0070 
GPR64 -0.3369 -0.2584 -0.2204 -0.1057 0.0369 
DNAJC6 -0.3696 -0.2578 -0.2995 -0.1153 0.0210 
CCNG2 -0.3062 -0.2509 -0.2592 -0.0220 0.1024 
SYNC -0.4219 -0.1569 -0.1438 -0.0456 0.0025 
EPHA4 -0.5011 -0.1107 -0.1015 0.0055 0.1131 
FOXE1 -0.3234 -0.2023 -0.1201 -0.0620 -0.0220 
NUSAP1 -0.3207 -0.1634 -0.1055 -0.0019 -0.0530 
NCAPG -0.2482 -0.1545 -0.0300 0.0560 -0.0160 
KITLG -0.2725 -0.2165 -0.0842 0.0483 -0.0705 
WNT6 0.3217 -0.3095 -0.1954 -0.1677 0.0600 
TLR6 -0.3320 -0.3530 -0.2925 -0.2457 -0.1459 
SLC2A3 -0.4514 -0.6810 -0.7332 -0.1950 -0.0879 
TMEM100 -0.3282 -0.7458 -0.7777 -0.0010 0.0479 
FLVCR2 -0.2802 -0.4531 -0.5111 -0.1520 -0.1199 
IGF1 -0.3663 -0.8193 -0.7820 -0.2964 -0.2050 
FGF18 -0.3691 -0.4585 -0.3789 -0.1047 0.0128 
BMP4 -0.2754 -0.4010 -0.3422 -0.1348 -0.0025 
C1orf106 -0.2952 -0.5104 -0.3716 -0.2088 -0.0713 
TXNIP -0.3978 -0.6334 -0.4821 0.0071 -0.0823 
MYCN -0.5207 -0.9847 -0.6610 -0.1577 -0.0694 
CYP1B1 -0.4264 -0.7071 -0.5211 -0.1683 -0.1196 
PDZRN4 -0.4689 -0.4807 -0.4885 -0.1096 -0.0939 
TRIM38 -0.2400 -0.2238 -0.1729 -0.0771 -0.0208 
SEMA3A -0.2982 -0.2980 -0.2681 -0.1752 -0.1663 
C5orf54 -0.3089 -0.2928 -0.2234 -0.1178 -0.0959 
NCOA3 -0.2522 -0.2755 -0.1955 -0.1078 -0.0968 
ADAMTS1 -0.4051 -0.4433 -0.2441 -0.0925 -0.0930 
NDC80 -0.2184 -0.3513 -0.1762 -0.0183 0.0183 
STYK1 -0.2764 -0.2968 -0.3718 -0.2957 -0.1344 
NOX4 -0.3271 -0.3982 -0.4322 -0.2949 -0.1359 
C1orf115 -0.2507 -0.3284 -0.3698 -0.1433 0.0850 
SERPINB13 0.2661 0.1919 0.2419 0.1552 0.2402 
C22orf29 0.3252 0.2418 0.3300 0.2302 0.2887 
OTOR 0.3295 0.2744 0.4579 0.2342 0.5747 
 
We validated a number of the top E2-regulated genes shared between cell lines by qRT-PCR.  
PEO4 and PEO1 cells were treated as described in Chapter 2 for microarray studies.  Gene 





Figure 29: Validation of E2-regulated genes identified by microarray.  PEO1 and PEO4 
cells were hormone-deprived and treated with vhc, 1 nM E2, E2 + 1 µM ICI, or ICI alone.  
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APPENDIX D 
BATCH EFFECT ANALYSIS OF CLINICAL SAMPLES IN CHAPTER 2  
Because the samples described in Chapter 2 were procured from four different medical centers, 
we conducted batch comparisons to rule out variation due to differences in tissue source.  These 
analyses were performed by Tianzhou Ma. 
D.1 SURVIVAL ACROSS PATIENT COHORTS 
We first compared survival between sites.  As reflected in Table 6, overall survival did not differ 
significantly between patients at different centers.  Time on endocrine therapy also did not vary 




Figure 30: Kaplan-Meier analysis of overall survival in patient cohorts from 




Figure 31: Kaplan-Meier analysis of time on endocrine therapy in patient cohorts in 
Chapter 2. Plot shows fraction survival on y-axis and time on endocrine therapy (days) 
on x. 
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D.2 NANOSTRING DATA ACROSS PATIENT COHORTS 
Comparisons of NanoString data also revealed no significant sub-cohort associations with regard 







Figure 32: EndoRx gene expression by all 70 HGSOC patients.  
We compared expression of all 350 genes in the EndoRx code set 






Figure 33: Comparison of total library counts from HGSOC 
samples across sites. As an additional batch effect test, we compared 
total NanoString counts across different tissue source sites. 
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APPENDIX E 
ADDITIONAL IMMUNOBLOTS SHOWING ER TURNOVER 
This appendix contains the additional blots comparing ER degradation in 2-D vs. ULA, initially 
described in Section 3.2.  Hormone-deprived cells were plated in 2-D or ULA and treated with 
vhc, E2, ICI, or 4OHT as indicated.  ER levels were assessed by immunoblot.  No significant 
difference was observed in degradation between 2-D and ULA for any of the cell lines assessed. 
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Figure 34: ER degradation in 2-D and ULA.  Hormone-deprived cells were plated in 2-
D or ULA and treated with vehicle, 1 nM E2, 1 µM ICI, or 1 µM 4OHT for 4 or 24 hours 
as indicated.  Performed by M. Boisen. 
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APPENDIX F 
SUPPLEMENTARY DATA FROM CHAPTER 4 
F.1 EFFECT OF MENOPAUSAL STATUS ON E2SIG EXPRESSION 
This appendix contains supplementary data for Chapter 4.  We first compared gene expression 
between samples from pre-menopausal and post-menopausal patients.  The heat map below 
Figure 35: Changes in gene expression across normal endometrium samples by 
menopausal status.  Heat map is colored by log2FC expression vs. median for each 
gene.  Color bar above the heat map reflects pre- (blue) or post-menopause (green). 
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depicts gene expression across all normal endometrium samples.  Pre- and post-menopausal 
cases did not cluster independently. 
F.2 DIFFERENTIALLY EXPRESSED GENES BETWEEN NORMAL 
ENDOMETRIUM, ENDOMETRIOSIS, ATYPICAL ENDOMETRIOSIS, AND EAOC 
The table below lists clusters of genes differentially expressed between normal endometrium, 
benign endometriosis, atypical endometriosis, and EAOC (Fig. 18).  Genes were identified by 
ANOVA as described in Chapter 4. 
 
Table 14: Differentially expressed genes between endometriosis and EAOC. 
Cluster 1 Cluster 2 Cluster 3 Cluster 4 
TGFA EZR FJX1 SLC22A5 
C1orf116 KLF5 PSD3 CDCA7 
BCAR3 MUC1 RARA ITPK1 
TLE3 CUEDC1 NFIB MYLIP 
KIAA1217 CYB561 NFIA ZMIZ1 
OSBPL3 TJP3 GSN C5orf13 
ITGB4 RAB17 GAS6 CGNL1 
SLC7A5 UBE2H DNAJB4 GREB1 
BCL2L11 FZD6 FBXO32 OLFML3 
PTPRE NCOA3 IGFBP5 RNF144A 
SHB PAX8 CALD1 OLFM1 
IFNAR2 SLC25A29 IGFBP4 WT1 
ARL4C SLC30A1 VIM LONRF2 
MARCKS ENPP5 GFRA2 ZBTB38 
NCF2 CPD TIPARP PRLR 
PLAU SCD FOS DAAM1 
SLC39A14 PKP2 DUSP1 EGFR 
ADM MYB THBS1 RND3 
TAPBP DEPDC6 CYR61 ESR1 
PRKCD BICD1 ARNTL PGR 
LIMK2 MCM10  MTUS1 
GCLM UHRF  ZFP36L2 
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LRP8 DTL  CAMK2D 
RNF213 PPAT  PODXL 
RHOF GINS2  MLPH 
RASGRP1 ONECUT2  ALDH3A2 
FGF18 PTPRH  NCOR1 
CTSC HNF1B  ARID5B 
PDGFRL PDZK1  PPP1R3C 
SLC7A2 SLC2A1   ASCL1 
PDK3 MPZL2  C20orf160 
PLOD2 EHF  SAMD4A 
ESR2 TMPRSS2  TUBB2A 
PHLDA1 CA8  RHOQ 
GALNT10 FAM174B  INPP4B 
RHOBTB3 TRAP1  TXNIP 
TSPAN5 SLC35A3  CEP68 
 TPD52L1  C6orf89 
 TP53  LIFR 
 HELLS  NCOA1 
 AKAP1  USP25 
 RBBP8   
 NCOA2   
 MDN1   
 RIF1   
 NRIP1   
 C19orf6   
 USP53   
 TGIF2   
 MPPED2   
 SPDEF   
 GALNT4   
 FAM46C   
 ATP2A3   
 SIX1   
 BMP7   
 ID2   
 EPHA4   
 IGFBP3   
 DKK1   
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F.3 FGF18 IS ESTROGEN-REPRESSED IN OVARIAN CANCER. 
FGF18 was one of the 207 genes identified by meta-analysis that was included in the E2sig.  
FGF18 is an estrogen-repressed gene.  Below are data from our preclinical models (cell lines and 
explants) supporting this. 
In PH053 explants, FGF18 expression was increased by the addition of ICI or 4OHT 
(Fig. 36, not significant).   RNA from the explant experiments described in chapter 2 was run on 
the NanoString platform.  Samples from three wells were pooled (n=3 explant pieces per well) to 
generate three replicates. 
 
Figure 36: ER-regulated FGF18 expression in PH053 
explants. Samples from three wells (n =3 explant pieces per 
sponge) were pooled to generate replicates.   Gene expression 
was analyzed by NanoString.  NanoString analysis was 
performed as described in Chapter 2.  Each dot represents a 
pooled sample.  Bars show median. 
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In PEO4 cells, FGF18 was significantly repressed by 8-hour treatment with E2 (p=0.001).  This 
repression was blocked by addition of ICI (Fig. 37).  The data shown below are from the 
NanoString experiment described in Chapter 2.   Notably, FGF18 was also significantly 
repressed by E2 in the microarray analyses (Fig. 3, Table 13). 
 
Figure 37: FGF18 is E2-repressed in PEO4 cells.  PEO4 cells were 
treated with vhc, 1 nM E2, or 1 nM E2 + 1 µM ICI for 8 hours.  Gene 
expression was analyzed by NanoString as described in Chapter 2.  Bars 
represent the average of three biological replicates.  Error bars show 
standard deviation.  Significance was determined by one-way ANOVA. 
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